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AEMs Attenuated Extracolonic Manifestations
APC Adenomatous Polyposis Coli
C Cytosine
Cdks Cyclin dependent kinases
CHRPE Congenital Hypertrophy of the Retinal Pigment Epithelium
CRC Colorectal Cancer
DCBE Double contrast barium enema
ELISA Enzyme-Linked Immunosorbent Assay
FAP Familial Adenomatous Polyposis Coli
FOBT Faecal Occult Blood Test
FS Flexible Sigmoidoscopy
G Guanine
HNPCC Hereditary Non-Polyposis Colorectal Cancer
IGFIIR Insulin-like growth factor II receptor
Ki-ras Kirsten ras




PAGE Polyacrylamide Gel Electrophoresis
PCR Polymerase Chain Reaction
PEG Polyethylene Glycol
PIT Protein Truncation Test
RER Replication Error
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RFLP Restriction Fragment Length Polymorphism
SSCP Single Strand Conformational Polymorphism
T Thymine or Tumour
TGFB RII Transforming Growth Factor Beta Receptor II
TRAP Telomeric Repeat Amplification Protocol
3'UTR 3' Untranslated region
WGLF Whole Gut Lavage Fluid
Abstract
Early colorectal cancers (CRC) can be cured with surgery. The five year survival for
all stages of the disease remains around 40%. A survival improvement could be attained
by increasing the detection of early cancers. Key genes are mutated at specific steps in
colorectal carcinogenesis. Telomerase activity has been detected in 90% ofCRC. The
identification of cancer mutations, or telomerase activity in stool samples may be
specific and non-invasive methods by which early colorectal cancers can be detected.
All studies to date have encountered problems with impurities in stool inhibiting the
polymerase chain reaction (PCR) amplification. Whole gut lavage fluid (WGLF) may
provide a sample that is more amenable to molecular analysis. Some individuals have an
increased risk of developing CRC, possibly because they have increased numbers of
cells containing mutations in cancer genes in the colon. Methods developed for early
CRC detection could be exploited to investigate increased cancer susceptibility. In this
thesis I assess suitability ofWGLF for PCR analysis. I also explore the feasibility of
early CRC detection, by examining multiple mutation sites in DNA extracted from
WGLF. Telomerase activity has been detected in saline washings from CRC pathology
specimens. Thus, I also explore the possibility of detecting telomerase activity inWGLF
samples. Finally, by examining synchronous colorectal cancers, I examine the possibility
ofmutational mosaicism in colorectal epithelium.
DNA was extracted from WGLF obtained pre-operatively from 40 patients
undergoing cancer resections. This was analyzed for mutations in 4 genes commonly
altered in CRC. Analysis consisted of a PCR/restriction enzyme enrichment strategy for
Ki-ras and p53 mutations, while APC and Transforming growth factor beta receptor II
(TGFfiRII) mutations were analyzed by non-enriched single strand conformational
polymorphism (SSCP). There were 26 mutations in 18/40 primary tumours (45%); 7
Ki-ras, 2 p53, 2 TGFfiRII and 15 APC. In the WGLF 2/7 Ki-ras mutations; 2/2 p53
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mutations; 0/15 APC mutations; 0/2 TGFfi R1I mutations were detected. PCR inhibition
was encountered and mutations were only detected with the enriched techniques. To
assess the potential of detecting telomerase activity in cancer detection, WGLF from 6
patients was examined using the telomerase repeat amplification protocol (TRAP).
Initial validation indicated telomerase activity could be detected in the protein extract
equivalent to 60 cells per reaction. Analysis ofWGLF samples indicated that
polyethylene glycol (PEG) at high concentrations inhibited the PCR portion of the
TRAP assay. Dilution of the WGLF samples, to give PEG concentrations that allowed
PCR, still did not yield positive TRAP assay results. This is possibly due to the dilution
of telomerase to concentrations below the sensitivity of the assay. Spiking diluted
WGLF samples with 103 cells from telomerase positive cell lines still yielded negative
results.
Identical APC mutations in synchronous CRC would strongly support the notion of
mosaicism. In a related line of investigation to identity potential research uses for the
molecular analysis ofWGLF, I initially examined synchronous colorectal cancers for
APC mutations. In 12 cases the mutation cluster region ofAPC was examined. No
identical APC mutations were identified. However, a replication error phenotype was
identified in 20% of cases, suggesting an underlying mismatch repair deficiency might
predispose to synchronous cancers.
While DNA extracted from WGLF is suitable for PCR analysis, many samples are
lost due to contamination or insufficient DNA. WGLF genetic diagnosis requires
selective mutation enrichment, other methods used for mutation detection are too
insensitive. TRAP inhibition has to be overcome to exploit the detection of telomerase
activity in WGLF. Genetic moasicism was not identified as a mechanism for increased
cancer risk by studying synchronous cancers.
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Summary
The genetic mutations that drive carcinogenesis are known in great detail for the
epithelium of the colon and rectum. The early detection of these tumour specific
mutations in clinical material holds promise as a tool for early diagnosis and screening
for colorectal cancer. This may be of particular use in people with a substantially
increased risk of developing colorectal cancer, in whom there is a strong case for close
surveillance. Traditionally the only certain way to achieve such surveillance has been
repeated colonoscopy and biopsy. These are expensive procedures that carry their own
morbidity and compliance cannot always be guaranteed. Recent work has demonstrated
the value of orally administered solutions of polyethylene glycol (used for bowel
preparation prior to surgery or radiology) in monitoring patients with inflammatory
bowel disease. Similar samples may be of use in sampling exfoliated colonic cells and
could provide an non-invasive method of providing material for molecular genetic
surveillance. Such samples have already been shown to be potentially valuable targets
for PCR techniques. Point mutations can be detected in stool and colonic washings but
other mutation sites need to be exploited for population cancer screening. It is still not
known just how powerful this type ofmolecular surveillance is likely to be. Initial
validation of such molecular techniques for diagnosis must be undertaken before they
can be applied to asymptomatic subjects in high risk categories.
In this thesis I have assessed the value of colonic washings (in the form ofwhole gut
lavage fluid) obtained pre-operatively from patients undergoing cancer resections as a
source ofDNA for analysis ofmutations in 4 genes commonly altered in colorectal
cancer. DNA was extracted from whole gut lavage fluid from 40 patients undergoing
cancer resections. Analysis of cancer specific mutations in whole gut lavage fluid
consisted of a PCR/restriction enzyme enrichment strategy for Ki-ras andp53
mutations, while APC and TGFfi R1Imutations were analysed by non-enriched single
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strand conformational polymorphism (SSCP). In this series, 18 patients (45%) had the
potential for a genetic diagnosis of their cancer on the basis of analysis of 4 genes, yet
only 4 (10%) were detected in the whole gut lavage fluid. My results demonstrate that
DNA extracted from whole gut lavage fluid is suitable for PCR analysis but many
samples are lost to further examination due to insufficient amounts of human DNA.
These findings indicate that stool-based genetic diagnosis requires selective mutation
enrichment before it will be useful in screening and that other methods commonly used
for mutation detection (e.g. SSCP) are not sufficiently sensitive. Additional methods of
mutation enrichment must be sought if these tests are to be used for screening.
Moreover, multiple sites or new loci would need to be analysed before such tests could
be comprehensive.
The identification of telomerase activity in up to 90% of colorectal tumours was
published whilst my research was in progress. Telomerase activity offers an opportunity
for a single molecular test for the detection of colorectal cancer, overcoming the
limitations ofmultiple point mutation detection. A commercial kit that employed the
Telomeric Repeat Amplification Protocol (TRAP) and an Enzyme linked
immunosorbent assay (ELISA) was used to try and detect telomerase activity in
previously stored unprocessed whole gut lavage fluid from 6 patients in the original
study population. No telomerase activity could be detected in these samples. Spiking
diluted whole gut lavage fluid samples with 103 cells from telomerase positive cell lines
still yielded negative results suggesting the presence of a reaction inhibitor.
Previous work from Edinburgh examining the extra colonic manifestations of
Familial polyposis coli (e.g. mandibular osteomas and congenital hypertrophy of the
retinal pigment epithelium (CHRPE)) has shown a preponderance of such lesions in
patients with replication error positive (RER+) cancers. The mismatch repair (MMR)
deficiency implied by an RER+ phenotype may allow incorporation of initially silent
mutations in key genes (e.g. APC) into apparently normal tissues at embryogenesis.
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Such individuals would be mosaics for these mutations and thus may have an increased
colorectal cancer risk. It had been hoped APC analysis ofwhole gut lavage fluid from
individuals with a strong family history of colorectal cancer would enable elucidation of
this hypothesis by allowing sampling of the entire colonic mucosa. My earlier work has
shown that APC analysis in whole gut lavage fluid is not possible.
To further pursue the hypothesis ofmosaicism I examined synchronous colorectal
cancers for identical APC mutations. The discovery of identical APC mutations in
synchronous cancers would strongly support the notion ofAPC mosaicism. In 12 cases
the mutation cluster region ofAPC was examined. In no case was identical APC
mutations identified. A RER+ phenotype was identified in 20% of cases suggesting an
underlying MMR deficiency might predispose to synchronous cancers. This does not




This thesis explores the possibility of exploiting the current knowledge of colorectal
cancer genetics for use in the early detection of colorectal cancer and hence screening.
In the last ten years much has been learned about the various genetic mutations that are
frequently found in colorectal cancer. Although the picture of colorectal carcinogenesis
is not complete, enough is known to allow us to start considering genetic techniques for
potential screening applications.
It is the nature of colorectal cancer that has allowed such detailed genetic analysis.
Colorectal cancer is a common Western disease and there is a wealth of pathological
and clinical material available for examination. Furthermore there is unique access to
cancers at different stages of progression providing information about all stages of the
disease. The systematic stepwise progression of colorectal cancer from benign adenoma
to invasive carcinoma, championed by Vogelstein, is now widely accepted. In accepting
this theory it is recognised that although not present in every cancer certain specific
mutations occur in pre-malignant adenomas. Detecting these mutations in clinically
obtained samples such as whole gut lavage fluid offers a specific method of early
colorectal cancer detection and thus obvious screening possibilities. False positive
results and low specificity are a major failing of present faecal occult blood screening
techniques.
Recent developments have focused on the rarer inherited forms of colorectal cancer,
Familial Adenomatous Polyposis Coli (FAP) and Hereditary Non-Polyposis Colorectal
cancer (HNPCC). Rigorous study of large kindreds with these conditions has
highlighted two areas of pathogenesis involving the adenomatous polyposis coli (APC)
gene in FAP and a family of genes involved in mismatch repair in HNPCC. These
developments would suggest that even if genetic screening of the general population
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proves to be impractical, targeted genetic screening for persons at risk of inherited
colorectal cancer could prove fruitful and cost effective.
Telomerase is an enzyme that by employing an integral RNA template maintains
telomere length in embryonic stem cells. It is not normally found in mature epithelial
cells. Telomerase activity can be detected in 90% of colorectal cancers and colorectal
cancer cell lines. The detection of telomerase activity in clinical material may offer a
single target for which molecular techniques could be exploited for screening purposes.
It is thought that individuals with an inherited cancer susceptibility through a
deficiency in DNA mismatch repair (e.g. in HNPCC) accumulate somatic mutations in
genes critical to the development of colorectal cancer. It is conventional to regard these
secondary mutations as events in the founder cells of neoplastic clones. However other
possibilities exist such as mutational mosaicism acquired in cancer genes at an early
stage of development. Successful development of genetic tests for the early detection of
colorectal cancer may ultimately be used to elucidate the mechanisms of carcinogenesis
in susceptible individuals.
In this thesis I discuss the implications of screening by conventional techniques and
discuss the recent advances in our understanding of colorectal carcinogenesis. The
potential for genetic tests to be used in early colorectal cancer detection has been
recognised but remains to be fully evaluated. With this in mind I then discuss my
research which focuses on three main areas. Firstly a proof of principle study to
evaluate the systematic analysis of four cancer gene mutations frequently associated
with colorectal cancer in whole gut lavage fluid obtained from sporadic colorectal
cancer cases. Secondly a preliminary study validating an assay to detect telomerase
activity in whole gut lavage fluid. Finally I shall attempt to address the possibility of
mutational mosaicism as a cause for increased colorectal cancer susceptibility by
analyzing a small subgroup of patients that have synchronous colorectal cancers.
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1.1 Sporadic colorectal cancer
Colorectal cancer is the second most common cause of cancer death in the United
Kingdom. It accounts for 22 deaths per 100,000 population in Scotland (Scottish
Health Statistics 1996) and in 1994 there were 3267 new cases in Scotland (Scottish
Intercollegiate Guideline Network (SIGN) 1997). The life time risk of sporadic
colorectal cancer in the general population is 6% (Brown 1995; Bond 1997). The major
form of treatment remains surgical resection with the addition of various adjuvant
therapies for advanced disease. Despite many technological advances in medicine the
overall five year survival for colorectal cancer has remained unchanged at around 30 -
40% (SIGN 1997). A patient's individual prognosis depends on the invasiveness of the
lesion at the time of surgery. Dukes' A adenocarcinomas have a much better five year
survival than Dukes' stage B and C (Mulcahy 1997). Unfortunately at present the
majority of cancers are stages B and C at the time of surgery (Stower 1985).
Improvements in diagnostic techniques that enable earlier diagnosis will result in more
patients undergoing surgery for Dukes' A carcinomas and premalignant lesions
allowing cure rather palliation.
High risk sub-populations
Certain sub-groups of the population have been shown to have an increased risk of
colorectal cancer. Patients who have previously undergone surgical resection for
colorectal cancer remain at an increased risk of developing a second primary
(metachronous) cancer (Fante 1996). Parents and siblings of patients with adenomatous
polyps also have an increased risk of developing colorectal cancer. The relative risk
when compared to spouse controls was 1.78 rising to 2.59 if the patient had an
adenoma diagnosed before the age of 60 (Winawer 1996). Similarly, first degree
relatives of patients with colorectal cancer have an increased relative risk of 1.9 for
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developing adenomatous polyps and hence, presumably, the potential to develop a
carcinoma (Bazzoli 1995).
Due to the common nature of colorectal cancer chance family clusterings are
recognised. However certain families have a strong family history of colorectal cancer
and a genetic predisposition to colorectal cancer has been established in two conditions.
Familial Adenomatous Polyposis (FAP) (Kinzler 1991) and Hereditary Non-polyposis
Colorectal Cancer (HNPCC) (Lynch 1993). FAP is a dominantly inherited condition in
which affected individuals develop numerous adenomatous polyps in the colon in their
first or second decade; progression to colorectal cancer occurs in all affected
individuals by the fourth decade if prophylactic surgery is not undertaken. In the west
FAP cancers account for approximately 1% of all colorectal cancers (Cunningham
1996). HNPCC is characterized by an early age of onset of the disease, typically before
the age of 50, with a tendency for lesions to be on the right side of the colon.
Histologically the tumours tend to be mucinous or poorly differentiated, and there are
more Dukes' stage A and B carcinomas than in colorectal cancer generally (Lynch
1993). The International Collaborative Group on HNPCC has proposed a series of
clinical criteria (the Amsterdam criteria) by which to diagnose HNPCC (Vasen 1991).
These are i) three or more relatives with histologically verified colorectal cancer, one of
whom is a first degree relative of the other two; ii) colorectal cancer involving at least
two generations; and iii) one or more colorectal cancer cases diagnosed before the age
of 50. All three criteria are required for the diagnosis ofHNPCC. The Amsterdam
criteria are clinical criteria and as such are necessarily very stringent. They were
established before the genes responsible for HNPCC had been identified. HNPCC may
account for as much as 6% of colorectal cancer cases (Lynch 1993) although more
recent studies suggest its incidence is lower at 0.3 - 1.4 % of all colorectal cancer
(Evans 1997).
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It is now evident from genetic analysis that mismatch repair mutations are identified
in families that do not fulfill the Amsterdam criteria but have a strong family history of
colorectal cancer. Similarly not all kindreds that fulfill the Amsterdam criteria harbour a
detectable mutation in the mismatch repair (MMR) genes (Liu 1996b). There would
appear to be a less definite distinction between a strong family history and true HNPCC
(by the Amsterdam criteria) when the genetic information is taken into account.
Families that fulfill the Amsterdam criteria may represent one end of a clinical spectrum
which merges with families with a strong family history of colorectal cancer. Hence,
when considered as a whole familial causes and patients with a positive family history
represent around 23% of all colorectal cancer (CancerNet 1997).
These sub-populations and their first degree family relatives represent a group in
whom surveillance and screening would offer a significant benefit.
1.2 Population Screening
Screening for a disease is justified when the disease is common and associated with
serious morbidity and mortality, and when early detection and treatment of the disease
results in improved prognosis relative to usual treatment. There must also be evidence
that the potential benefits outweigh the potential harms and costs of screening
(Winawer 1997). The natural history of colorectal cancer fulfills the disease criteria as a
condition highly suitable for screening. Currently there are several candidate screening
approaches. The ideal screening test itself should be simple, cheap and repeatable. It
should be specific and have a high degree ofpatient compliance. No test currently




i) Digital rectal examination
Digital rectal examination alone has generally been dismissed as a screening method
since interpretation is subjective and the examination is limited to less than 10% of the
large bowel (Bennett 1994). Routine digital rectal examination provided no significant
reduction in mortality from distal rectal cancer (Herrington 1995).
ii) Faecal Occult Blood Testing
The simplest technique of screening for colorectal cancer is the faecal occult blood
test (FOBT). It has been estimated that two thirds of cancers bleed to levels detectable
in stool in the course of a week (Winawer 1997) and the aim of the FOBT is to identify
this. The Haemoccult ® test (Smith Klein and Beecham) is commonly used and is based
on a slide preparation of guaiac gum which exploits the pseudoperoxidase activity of
haemoglobin to catalyse the phenolic oxidation of an indicator substrate. Certain foods
exhibit peroxidase activity (red meat, turnips and horseradish) and dietary restrictions
are therefore required to reduce the number of false positive tests. Vitamin C (by
inhibition of the peroxidase reaction) can lead to a false negatives as can inaccurate
interpretation of the slides. Because of the intermittent nature of bleeding from
colorectal cancer a single FOBT obtained from digital rectal examination is of little use
and repeated sampling of consecutive stools for three days is recommended (Winawer
1997).
Reported compliance for FOBT ranges from 30 - 90% and tends to decline with
study progression. Younger subjects are less likely to comply and higher rates of
compliance are found in individuals with a higher educational level and in subjects with
a family history of the colorectal cancer (Winawer 1997). Two large studies in Europe
have evaluated this test, the larger of these studies was from Nottingham (Hardcastle
1996). This was a prospective study of 152,850 subjects aged between 45 -74 years
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using unrehydrated tests and 2 yearly rescreen. In the screened group 60% completed
at least one FOBT screening with 38.2% completing all tests offered. Although the
overall number of cancers in study and control groups were almost identical the
screened group had a 15% reduction in cumulative colorectal cancer mortality and
significantly higher percentage ofDukes' stage A cancers (20% compared with 11% in
the control population). A second study from Denmark has confirmed these findings
showing a similar number of cancers in each group but a significant reduction in the
cumulative colorectal cancer mortality by 18% along with a significant increase in the
number of early cancers when compared with control groups (Kronborg 1996).
One trial from Minnesota (Mandel 1993) has shown a significant reduction in
mortality in patients screened annually compared to controls (cumulative annual
mortality 5.88 per 1000 and 8.33 per 1000 respectively). This study employed
rehydrated slides for FOBT which increased sensitivity but lead to a concomitant
reduction in specificity (Winawer 1997). This study has met with some criticism
because the annually screened group also had a 38% higher annual colonoscopy when
rate compared with controls. The net result was that over one third of the participants
in the study group underwent colonoscopy over a 13 year period. Thus the results may
simply reflect the value of colonoscopic screening (Bennett 1994). Others would attach
less significance to this potential bias. When a simple screening test is applied to a large
population and is followed by a definitive diagnostic test there will be some random or
accidental benefit from the diagnostic test itself. This effect for the Minnesota trial has
been calculated at between 6-11%, not enough to account for the observed reduction in
mortality (Bond 1997), thus supporting the use ofFOBT in screening the general
population.
A simple indirect screening test repeated at definite intervals does not have to be
highly sensitive to be effective as long as it reliably detects developing neoplasms before
they become incurable; application of the FOBT at one time may have a low sensitivity
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but repeated use in a screening program over time maybe highly sensitive and effective
(Bond 1997). Whilst mass population screening would inevitably lead to increased
detection of colorectal cancers the poor specificity of the test would certainly lead to
more colonoscopies being performed for other bleeding conditions of the bowel. This
has serious resource implications. FOBT will also certainly miss a proportion of
cancers. The impact of false positive and negative test results on the general population
are also important considerations when contemplating mass population screening by
FOBT. These considerations must be weighed against any potential benefits ofFOBT.
The case for regular FOBT for the general population appears compelling yet the
Scottish National Clinical Guidelines concluded that the available evidence on FOBT
did not warrant screening of the Scottish population at the present time (SIGN 1997).
A negative FOBT can lead to a false sense of security although the majority of
cancers detected by FOBT are at Dukes' stage A and B (Hardcastle 1996) up to 62%
of advanced stage cancers (Dukes' stage C and D) are missed by initial FOBT with 62-
76% of these being in reach of a flexible sigmoidoscope (Schnell 1994). This suggests
FOBT should be augmented in some way; indeed a recent prospective study has shown
that the addition of flexible sigmoidoscopy (flexible sigmoidoscopy) to FOBT screening
can yield a four fold increase in the detection of neoplastic lesions in the general
asymptomatic population (Berry 1997).
Hi) Flexible Sigmoidoscopy and Colonoscopy
The use of flexible sigmoidoscopy (and colonoscopy) as screening techniques
requires significant medical input and they are invasive procedures with their own
morbidity and mortality. Flexible sigmoidoscopy has several advantages over FOBT.
The bowel can be visualised directly enabling biopsy or removal of suspected cancers or
polyps. However it requires a hospital visit and preparatory enema, and the examination
itself produces some abdominal discomfort. Around 40% of cancers will not be
visualised with a 60 cm. flexible sigmoidoscope (Wu 1995). False positive examinations
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are rare. Despite these limitations case control studies show that sigmoidoscopy can
significantly reduce the risk of death from distal cancers over a 10 year period for a
population at average risk of colorectal cancer. However patients dying from colorectal
cancer also had fewer rectal examinations, FOB tests and heath check ups (Newcomb
1992; Selby 1992). Screening the general population by flexible sigmoidoscopy can be
expected to detect 3 carcinomas per 1000 subjects but compliance varies widely
between 20 and 95% (Wherry 1994; Berry 1997).
The morbidity associated with screening endoscopy is 0.3% but the when compared
with the decrease in colorectal cancer mortality attributable to screening this
complication rate is acceptable (Kewenter 1996). The current recommendation of the
American Cancer Society, for populations at average risk and a negative initial
examination, is flexible sigmoidoscopy every 3-5 years from the age of 50 (Winawer
1997). Other data suggest that, following a negative examination, or polypectomy for
early tubular adenomas, cancer development is rare. Hence the interval between
examinations might be increased with safety. Even "once only" flexible sigmoidoscopy
could be an effective screening strategy in these instances (Atkin 1992).
Colonoscopy is a more invasive procedure requiring thorough bowel cleansing,
analgesia and sedation, necessitating day case admission to hospital. The morbidity
associated with diagnostic colonoscopy is low (around 0.1%) but rises if polypectomy
is performed (Kewenter 1996). Colonoscopy is currently the only available means of
clearly identifying the 42% of neoplastic lesions that lie beyond the reach of the flexible
sigmoidoscope and the 36% of lesions that are too small (less than 0.5 cm in diameter)
to be visualised by double contrast barium enema. Colonoscopy has been advocated as
a more appropriate initial screening procedure than FOBT (Wu 1995). There are no
controlled clinical trials examining colonoscopy as a screening method (Winawer 1997).
Mathematical models suggest flexible sigmoidoscopy every 5 years would reduce the
incidence of colorectal cancer in a population of 100,000 by 1,976 cases from 4,988 to
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3,013 and increased the life expectancy of the affected population by 8.6 years. The
number of deaths would be expected to decrease by 967, but this would be at the cost
of 3 deaths as a result of colonoscopy with 20 perforations and 49 major bleeding
episodes (Winawer 1997).
iv) Doable Contrast Barium Enema
Double contrast barium enema (DCBE) requires bowel preparation 24 hours prior to
the procedure, the instillation of barium and air per rectum, fluoroscopic monitoring
and exposure to x-rays. Around 5 - 10% of examinations are technically unsatisfactory
requiring further examination by other means and the sensitivity of DCBE ranges from
70 - 90% for polyps greater than 1 cm and early carcinomas (summarised in Winawer
1997). There are no controlled trials examining the effectiveness ofDCBE in screening
for colorectal cancer but indirect calculations would suggest an efficacy similar to
flexible sigmoidoscopy (Winawer 1997). A positive DCBE necessitates colonoscopy.
Genetic screening for inherited colorectal cancer syndromes
The rarity ofFAP and HNPCC and the technical difficulties in identifying mutations
makes genetic screening of the general population for these familial syndromes
impractical. However if the mutation is identified in a proband case, screening of close
family members is feasible in each syndrome. The fact that FAP and HNPCC are the
result of germline mutations (Bailey-Wilson 1986) allows the possibility of family
genetic screening to be considered. With FAP the dominant nature of its inheritance
permits screening by simple restriction fragment length polymorphism(RFLP) or protein
truncation tests (PTT) on blood samples once the germline mutation from the proband
has been identified (Prosser 1994). The identification of the adenomatous polyposis coli
(APC) gene has allowed predictive testing for FAP either by linkage analysis or
mutational analysis. Linkage analysis is more restricted than mutational analysis.
However mutational analysis requires characterisation of the mutation which is not
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always possible. Family members who are non-gene carriers by mutational analysis can
be reassured. Mutation carriers can be appropriately counselled and offered
prophylactic surgery (Cunningham 1996)
The situation for HNPCC is more complex. While it is known a high proportion of
HNPCC cases will have a germline mutation in one of the mismatch repair genes, not
all cases do. This is either because the mutation lies in a non-coding portion of the gene
or because not all the genes involved in MMR have been identified (Liu 1995; Liu
1996). Recent observations have emphasised the importance of constitutional mutations
in mismatch repair genes in a high proportion of patients with HNPCC (Liu 1996b).
The high cancer susceptibility of these patients probably derives from the fact that,
because of deficient DNA mismatch repair, they more rapidly accumulate somatic
mutations in genes critical to the development of colorectal cancer (Kinzler 1996).
However, for HNPCC the incomplete penetrance, the number of genes which can
potentially be mutated and the fact that not all potential target genes have been
identified means that screening is a more complex issue. Unless the prevalence of the
HNPCC genotype and classic syndrome is in the range of 50 cases per 10,000 or more
people, very favourable assumptions must be made for population wide genetic testing
to be cost-effective. If the prevalence of a homogeneous HNPCC syndrome is towards
the lower end of current estimates (0.5 - 10%) or if the HNPCC syndrome were to be
much more heterogeneous than observed in known HNPCC families, it appears unlikely
that population wide genetic screening can achieve acceptable levels of cost-
effectiveness (Brown 1995). These variables of penetrance also pose difficult problems
about screening the family members ofHNPCC kindreds. The heterogeneity ofMMR
mutations (Weber 1997) and the number of genes to be examined have practical
implications even when restricting screening to family members. The risk to related
individuals in kindreds that fulfill the Amsterdam criteria is variable (Dunlop 1997). The
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risk to family members of kindreds with a positive family history that do not fulfill the
Amsterdam criteria is indeterminate.
Adenomas in HNPCC are often flat and have a greater tendency to progress to
cancers than adenomas arising in the average risk population (Lynch 1993).This
suggests a shorter surveillance interval is required than that for the average population.
A period of 1-2 years between colonic examinations is currently recommended (Vasen
1995; Winawer 1997). Because of the proximal distribution of cancers in HNPCC the
entire colon must be visualised preferably by colonoscopy (Winawer 1997). Due to the
underlying DNA instability in patients with such germ line mutations they remain at risk
of further metachronous colorectal cancer after operative removal of the first
carcinoma. Moreover, their close relatives are also at risk.
There is good evidence that there is a group of people with an affected first degree
relative that is at an increased risk of colorectal cancer, yet who do not fulfill the
Amsterdam criteria for inherited genetic disease. It has been calculated that people in
the general population with one affected first degree relative have a relative risk of 1.7
(Fuchs 1994) and it is recommended that these patients should undergo colonoscopic
screening from the age of40 particularly if the affected relative had the diagnosis made
before the age of 55 (Levin 1992). Objective data would only tentatively support
colonoscopic screening in asymptomatic patients if their life time risk were 1 in 2,
however the psychological benefit of counseling and screening subjects with an affected
first degree relative must also be considered (Mulcahy 1997).
These patients would therefore constitute a rewarding subset of the general
population at which to direct appropriate screening tests. The Scottish Guidelines for
the screening of subjects in high risk groups are that first degree relatives should be
offered screening when FAP or HNPCC is diagnosed. Total colonoscopy or double
contrast barium enema should be offered, starting in the teens for FAP and twenties for
HNPCC. Colonoscopy should be performed every 2-3 years depending physical
28
condition and compliance. For those at risk ofFAP more frequent 1-3 yearly flexible
sigmoidoscopy should be considered (SIGN 1997). The cumulative morbidity of
colonoscopy repeated every 1-2 years from the age of 20 could be unacceptable and
any test that is less invasive with a comparable specificity would be an advantage.
Genetic based tests may fulfill these criteria.
Cost effectiveness of potential screening strategies
Comparison of the various screening methods would require large multicentred
studies to produce meaningful answers and so far has not proved practicable. One
approach has been to devise a mathematical model based on published results to try to
predict the cost-effectiveness of the various screening methods (Lieberman 1995). By
making a number of assumptions regarding screening intervals, prevalence of colorectal
cancer, cancer mortality and colonoscopy morbidity, Lieberman has shown that FOBT
alone, although cheapest per life saved, prevents fewer cancer deaths than any other
method of screening. Once-only colonoscopy would have the greatest impact on
colorectal cancer morbidity, assuming that a polypectomy prevents subsequent cancer
development in most patients. However, compliance was an important factor in
determining the effectiveness of all the screening programs (Lieberman 1995). In a
critical review of the current data Bond concluded that the combination ofFOBT and
flexible sigmoidoscopy has the potential to reduce colorectal cancer mortality in the
general population by 50%, saving some 35,000 lives a year in the USA (Bond 1997).
Further simulation studies showed that for a population of 100,000 the use ofFOBT,
followed by colonoscopy for patients testing positive , would reduce the incidence of
colorectal cancer by 2,378 cases (from 4,988 to 2,610). The number of expected deaths
would decrease by 1,330 with an increased life expectancy of 9.3 years. However it was
estimated there would be 52 deaths from complications of colonoscopy, 304
colonoscopy perforations and 741 major post colonoscopy bleeding episodes (Winawer
1997).
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Endoscopic screening is time consuming, expensive, and potentially hazardous but is
justified in subjects at high risk because of its sensitivity and specificity for neoplasia
(Mulcahy 1997). Identifying the point at which the benefits of endoscopy and radiology
are outweighed by their disadvantages is difficult and most would offer such
investigations if two or more first degree relatives were affected (Mulcahy 1997). The
greatest cost of screening is the diagnostic evaluation prompted by a positive screen.
Any test that reduces the number of false positive and hence subsequent investigations
(i.e. improves the specificity if the screening test) will thus improve the cost-
effectiveness of screening (Bond 1997). Again the use of genetic based tests may
address this issue.
Summary of current screening issues
Although FOBT is the most cost effective method of screening, its lack of specificity
means that additional tests (colonoscopy, flexible sigmoidoscopy or DCBE) are
required to augment it. Such tests add significantly to the overall cost of colorectal
cancer screening. Development of a simple stool or gut lavage based test that has a
greater specificity than FOBT would constitute a substantial advance by reducing the
number of additional tests performed.
1.3 Mutations in exfoliated cells
In the following sections various mutations specific to colorectal cancers will be
discussed. Searching for these mutations in exfoliated cells contained in stool or colonic
effluent may provide a test by which colorectal cancer may be detected.
Colonic epithelial cells migrate from the lower third to the top of a crypt in between
3 to 4 days. The epithelial cells proliferate (i.e. enter S phase) at a rate of 1.2 cells / 100
cells / hour. Although specific areas of cell extrusion at the tips of the villi cannot be
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readily identified, in order to maintain a stable cell population, colonic epithelial cells
are apparently lost from the lumenal surface at a similar rate (Lipkin 1963). Thus it is
anticipated that stool and colonic effluent should provide a rich source of cells and
DNA for analysis. One would expect colorectal cancers to contribute to these
exfoliated cells.
Early evidence that cancer mutations can be detected in exfoliated cells was
provided by the analysis ofp53 mutations in urine samples from patients with known
bladder cancer (Sidransky 1991). Using PCR amplification techniques p53 mutations
were identified in DNA obtained the resected cancer. In three cases thep53 mutation
was then sought in DNA obtained from the sediment of pre-operatively voided urine.
Phage hybridisation techniques were employed to increase the sensitivity of the urine
tests. Identical mutations were found in the urine sediment DNA in each case. Mutant
alleles accounted for 1-7% of the recombinant clones. No false positives were detected
in six normal samples tested in a similar manner (Sidransky 1991). This study highlights
a sensitive and specific technique for detecting cancer specific mutations in exfoliated
cells. The disadvantage in this technique is that it requires prior identification of the
mutation from the resected cancer to allow the use of hybridisation techniques. This is
not possible when screening for an unknown cancer. Nonetheless the detection of
cancer specific mutations in the stool by molecular techniques holds promise as a more
specific screening test for colorectal cancer.
Certain key mutations have been implicated in colorectal carcinogenesis. By focusing
on Ki-ras, APC, p53, and TGFfiRII it may be possible to devise a strategy for
screening for colorectal cancer. The clonal expansion ofmutated cells in colorectal
cancer means that analysis for these genes would be selective for colorectal cancer
(Kinzler 1996). By choosing a mutation that occurs early in the adenoma / carcinoma
progression early or even pre-malignant lesions could be detected. The cellular material
exfoliated in faeces and other similar samples is likely to be degenerate. Any DNA
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present is likely to be fragmented either by bacterial DNases or apoptosis. The
polymerase chain reaction (PCR) can be used to specifically amplify small fragments of
DNA and this could be usefully employed in a genetic test for colorectal cancer.
Cancer mutations in stool
The genetic mutations associated with sporadic and hereditary colorectal cancer are
widely studied and are some of the best understood at the present time (Fearon 1990;
Kinzler 1996). The study of the rarer inherited colon cancer syndromes, FAP and
HNPCC, has lead to important advances in the understanding of sporadic colorectal
cancer. The principal concept for both hereditary and sporadic cancers is that the cancer
develops by accumulating mutations in several genes in stepwise manner resulting in a
progression from normal epithelium through adenoma to invasive carcinoma (Kinzler
1996). Mutations in APC, the gene associated with Familial Adenomatous Polyposis
(FAP), initiate the neoplastic process (Kinzler 1996) and tumour progression results
from accumulation of other mutations for example Ki-ras, p53, (Kinzler 1996) or
Transforming Growth Factor Beta Receptor II (TGFJ5 RIP) (Parsons 1995b).
Oncogenes such as Ki-ras are activated by mutations, tumour suppressor genes (e.g.
p53) are inactivated. Mutations in the mismatch repair genes produce an overall genetic
instability and hypermutable state which leads to a more rapid accumulation of the other
carcinogenic mutations (Kinzler 1996). These mutations and others, as yet unidentified,
act in concert to produce a carcinoma.
Ki-ras mutations associated with colorectal cancer have been detected in stool and
colonic washings of patients known to have Ki-ras mutations in the resected colorectal
cancer. The successful detection rate varied widely from 16 - 81 % cases (Sidransky
1992; Tobi 1994; Hasegawa 1995; Smith-Ravin 1995; Cruickshank 1996; Nollau 1996;
Villa 1996). p53 mutations in stool have also been detected by single strand
conformational polymorphism (SSCP) (Eguchi 1996). One study has even reported
identifying Ki-ras mutations in colonic washings obtained four years before the
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macroscopic lesion being detected (Tobi 1994) indicating a potential for pre-malignant
detection.
The DNA obtained from stool samples has been shown to be heavily contaminated
and can inhibit the polymerase chain reaction (PCR) used for genetic analysis (Smith-
Ravin 1995; Cruickshank 1996). Colonic washings obtained at endoscopy however may
be more suitable for genetic analysis by PCR techniques (Tobi 1994; Smith-Ravin
1995).
1.4 Whole gut lavage
Exfoliative cytology to aid the diagnosis of colorectal neoplasia was introduced
several decades ago (Bader 1951) with good results. The specificity of the technique
was compromised because the cytological characteristics of neoplasia could also be
found in cells shed from adenomas with severe dysplasia and as a response to
inflammation as in ulcerative colitis. (Rozen 1990; Wurerker 1993). The cumbersome
and complex methods for obtaining the specimens along with the introduction of
colonoscopy and the possibility of direct biopsy meant that the technique fell into
decline (Rozen 1990). The introduction of bowel preparation with balanced electrolyte
solutions has renewed interest in cytology, as it provided a simple and safe method for
obtaining rectal fluid that can be used for cytological analysis (Rozen 1990; Handy
1995) . Whole gut lavage fluid is the clear effluent obtained per rectum following bowel
preparation with polyethylene glycol balanced electrolyte solutions (Klean Prep ®
Norgine Harefield Middlesex UK). High IgG concentrations in whole gut lavage fluid
correlates well with disease activity and remission in patients with inflammatory bowel
disease. Its use in diagnosis of these conditions is however limited (Choudari 1993).
Whole gut lavage specimens have been shown to contain numerous inflammatory cells
in patients with inflammatory bowel disease (Handy 1995). Normal colonocytes are
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however an infrequent finding in whole gut lavage fluid (Brandt 1989; Wurerker 1993)
and malignant cells have been detected with varying degrees of success in 30-94% of
patients with adenocarcinoma (Brandt 1989; Rozen 1990; Gordon 1991; Tobi 1994).
Tobi et al found that 70% of the lavage samples were satisfactory for analysis and
identified 4/9 cancers and 8/19 adenomas (Tobi 1994). Brandt et al found 50% of the
lavage samples contained insufficient epithelial cells for suitable analysis and were able
to detect 4/14 (29%) of adenocarcinomas (Brandt 1989). However Gordon et al were
able to identify 9/9 cancers on examining the lavage fluid with 1 false positive in 18
normal control samples (Gordon 1991).
1.5 Mutations associated with Colorectal cancer
Systematic genetic analysis of colorectal cancers at different stages, ranging from
early adenomas to invasive carcinomas, has suggested that the steps required for the
development of colorectal cancer often involve the mutational activation of oncogenes
or with the loss of tumour suppressor genes (Vogelstein 1988). Vogelstein et al.
searched for ras mutations and allelic deletions in chromosomes 5, 17p and 18 in 192
colorectal cancers of varying stage. Mutations in ras were identified in 58% of
adenomas greater than 1 cm in diameter, and in 47% of carcinomas, but only in 9% of
adenomas less than 1 cm in diameter. Sequences on chromosome 5 linked to the gene
for familial adenomatous polyposis (APC) were lost in 29-35% of sporadic adenomas
and carcinomas (but interestingly not in tumours from patients with polyposis).
Chromosome 17p sequences were lost only in carcinomas but were found in 75% of
all colorectal carcinomas. No such losses were identified in adenomas. A specific region
in chromosome 18 was deleted in 13% of early adenomas, 47% of advanced adenomas
and 73% of carcinomas. Hence it can be seen that molecular alterations parallel the
development of adenoma to carcinoma, strongly suggesting that mutations in certain
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key genes are required for the stepwise progression in the development of colorectal
cancer (Vogelstein 1988). Advances in scientific techniques and knowledge have
enhanced this theory supporting the original concept. Current theory (summarised in
Kinzler 1996) suggests that APC acts as a gatekeeper to colonic epithelial cell
proliferation and that mutations in APC are the rate-limiting step in the progression of
colorectal cancer (Kinzler 1996). Other potential gatekeeper genes include NF1 in
Schwann cells, Rb in retinal epithelium. Normally wild type APC maintains a constant
cell population in the colonic epithelium and mutation ofAPC leads to a permanent
imbalance in cell proliferation promoting tumorigenesis. Similarly mutations in other
genes associated with colorectal cancer in the presence of normal APC do not lead to a
cancer formation implying the order of accumulation ofmutations may be important
(Kinzler 1996).
There is growing evidence to support these theories. Firstly, although FAP patients
develop many tumours inactivation of the inherited wild type APC allele is required for
adenoma formation (Ichii 1992). Also APC mutations have been found in the earliest
stage of colorectal cancer, the aberrant crypt foci, which are foci of dysplastic epithelial
cells in otherwise normal colon epithelial crypts (Jen 1994 ). These observations place
mutations in APC at the start of the adenoma / carcinoma progression. Secondly, in
contrast, cells with ras mutations are frequently found in aberrant crypt foci but if this
mutation is the first event the result is a non-dysplastic focus which has little potential
to progress (Jen 1994). Mutations inp53 occur near the transition from benign to
malignant lesion with an inactivating point mutation of one allele being the rate limiting
step (Baker 1990). Although p53 is mutated in over 80% of colorectal cancers patients
with germ-line mutations in p53 do not develop
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The genetic changes associated with colorectal carcinogenesis (modified from Kinzler 1996)
APC mutations initiate the neoplastic process with Ki-ras mutations enhancing adenoma
formation and p53 mutations involved in the progression to carcinoma. Other mutations in as yet
unidentified genes may influence other parts of the progression.
Mismatch repair deficiency confers a genomic instability allowing fast accumulation of relevant
mutations and faster progression to carcinoma
polyposis and are not even at high risk of developing colorectal cancer (Kinzler 1996).
These observations would supporting the theory that the order ofmutations is
important.
i) Ki-ras
The gene encoding Ki-ras spans between 35 - 40 kb on chromosome 12p with an
open reading frame of 567 bp in 4 exons. The fourth exon shows alternative splicing
with two alternative exons 4A and 4B. The gene with codon 4A encodes a membrane
bound polypeptide with a molecular weight of 21,660 daltons with intrinsic GTPase
activity. There is an associated pseudogene representing a processed mRNA version of
the gene (McGrath 1983). Specific point mutations (e.g. codons 12 and 13) in the ras
gene transform cultured cells (Land 1983) and confer neoplastic properties in vivo.
With increasing understanding it is clear the ras signaling pathway is extremely complex
(reviewed in Campbell 1998). Ras proteins are positioned at the inner surface of the
plasma membrane where they act as binary molecular switches regulated by a GDP /
GTP cycle. The proteins serve to transmit extracellular ligand mediated stimuli into the
cytoplasm. Point mutations producing amino acid substitutions at positions 12, 13 and
61 lock it in the GTP bound active state and make it insensitive to negative modulating
molecules. Activated ras proteins activate an ever increasing number ofmolecules in a
complex cascade ofwhich the main ras effector molecule is raf. Through a series of
serine / threonine kinases this cascade ultimately influences nuclear transcription factors
and gene expression.
Some 50% of colorectal cancers have such ras mutations (Bos 1987). Adenomas
greater than 1 cm have a similar rate ofmutation but fewer than 10% of adenomas less
than 1 cm have ras mutations (Vogelstein 1988). ras mutations are thought to be
weakly associated with malignant conversion because the frequency of ras mutations
among advanced cancers is similar to that among larger adenomas (Vogelstein 1988).
Analysis of the various dysplastic areas found in adenomas has shown ras mutations are
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more frequently found in areas ofmoderate dysplasia when compared to areas ofmild
dysplasia. Thus ras mutations may contribute to a more advanced morphological
phenotype during the late stages of adenoma progression but not directly to the
malignant transformation from adenoma to carcinoma (Ohnishi 1997). Dukes' stage B
and C cancers however show very significant differences in the type of ras mutation.
The metastatic potential of these tumours could be related to the nature of the genetic
alterations in ras rather than the hypothesis that Dukes C carcinomas eventually evolve
from Dukes B. G—»C and /or G—»T transvertions at codon 12 appear to endow tumour
cells with the capacity to metastasize whereas G—>A substitutions do not (Moerkerk
1994).
ii) p53
p53 is a highly conserved vertebrate gene encoding a tumour suppressor protein
which regulates the cell cycle in response to DNA damage. In normal cells p53 is an
unstable nuclear protein. Following genomic DNA damage however, p53 is stabilised
and activated as a transcription factor providing a crucial block to cell cycle progression
leading to growth arrest or apoptosis (Cox 1995). Loss of the normal function of the
p53 has been implicated in a wide variety of human cancers (Haffner 1995).
The gene encoding the p53 protein is located on chromosome 17p. The protein
consists of 393 amino acids with four structural and functional domains. The N-terminal
42 amino acids constitute a transcription activation domain that interacts with basal
transcriptional machinery positively regulating p53 gene expression. However some of
negative regulators ofp53 transcription (hMDM2 and adenovirus ElB-55Kd) also
mediate their action via these same amino acids (Levine 1997). Located between amino
acids 162-292 is a sequence specific DNA binding domain. This domain is protease
resistant and contains a Zn2+ ion essential for binding activity (Levine 1997). In this
domain residues lysine 120, serine 241, arginine 273, alanine 276 and arginine 283
make contact with the phosphate backbone of the DNA major groove. Residues lysine
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120, cysteine 277 and arginine 280 interact via H bonds with the DNA bases and
arginine 248 makes multiple H bonds in the minor groove (Cho 1994). An
oligomerisation motif is harboured in the COOH terminal portion (residues 324 - 355).
Tight dimers and dimer pairs form a remarkably symmetrical tetramer, held together
through multiple molecular interactions (Haffner 1995; Levine 1997). The C-terminal
37 residues form an open domain which readily binds DNA and RNA and regulates the
ability of p53 to bind to specific DNA sequences at its central core domain (Levine
1997).
Normally the concentration of p53 in the cell is low because of its relatively short
half life of approximately 20 minutes. It is degraded by the action ubiqutin proteases
(Levine 1997). One function ofwild type p53 is to act as a sequence specific
transcription factor which can activate genes possessing p53 consensus sites. p53 is
activated by DNA damage, such as double strand breaks by y radiation, UV irradiation
or chemical cleavage. Following DNA damage p53 protein levels are significantly
increased (Kastan 1991). The activation is proportional to the damage received
however the actual mechanism is unclear (Levine 1997). Once activated the tetramer
protein binds to the DNA sequence 5'-PuPuPuC(A/T); this sequence is repeated in two
pairs each arranged as inverted repeats (Levine 1997). It is this sequence specific
transactivation that mediates the growth-inhibitory action of p53. Growth inhibition is
elicited through specific binding of p53 to target genes and their subsequent activation.
(Pietenpol 1994). Products of some of the genes that are transcriptionally activated by
p53 include p21, MDM2, GADD45, Cyclin G, Bax, IGF-BP3 (Levine 1997).
Subtractive hybridisation techniques cloned the WAF1 gene which was strongly induced
by excess wild type p53. In addition over expression of WAF1 alone reproduced the
growth inhibitory effect of p53 (El-Deiry 1993). These observations suggest that some
of the growth arrest properties of p53 are mediated by the WAF1 gene product.
Independently cloned by other researchers WAF1 (or CIPI/SDI) encodes a protein
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product p21. This is a potent inhibitor ofmany cyclin dependent kinases (Cdks). These
enzymes are essential for transit through various stages of the cell cycle (Haffner 1995).
p53 may arrest cells in G1 by activating WAF1. The resultant p21, by inhibiting the
Cdks, in turn leads to hypophosphorylation of pRb, the protein product from the
retinoblastoma gene, subsequently blocking cyclin E2F-dependent transcription causing
cell cycle arrest (Haffner 1995). Normally pRb proteins are inhibitorily phosphorylated
by active Cdks enabling transit through Gl-S. Hence the growth inhibitory effect of p53
is mediated by induction of p21 and executed through under phosphorylation of pRb
proteins. (Haffner 1995). The protein p21 can interfere directly with DNA synthesis by
binding to proliferating cell nuclear antigen (PCNA) (Waga 1994). Attempts to isolate
inhibitors ofDNA synthesis in senescent cells also identified p21 (Haffner 1995). This
suggests that p21 directly inhibits DNA synthesis. Thus induction of p21 by p53 may
serve dual roles: preventing exit from G1 by inhibiting cyclin/Cdk complexes and in
parallel blocking replicative DNA synthesis directly by binding to PCNA.
p53 also plays a role in apoptosis induced by DNA strand breaks. Radiation induced
apoptosis in intestinal crypt cells of normal mice undergo extensive apoptosis. By
contrast intestinal crypt cells in p53 null mice fail to exhibit enhanced apoptosis (Clarke
1994). The apoptosis modulating protein Bax is rapidly activated by p53 and this could
promote p53 mediated apoptosis. (Selvakumaran 1994). In addition the transcription of
Bcl-2 (another apoptosis modulating factor with death inhibitory activity) is repressed
by p53. The Insulin like growth factor binding protein 3 (IGF-BP3) may also play a role
in p53 mediated apoptosis being transactivated by p53 and inhibiting the growth
promoting action of insulin like growth factor (Buckbinder 1995).
In the absence of functional pRb which is normally required for imposing a p53-
mediated G1 arrest, instead of producing a growth arrest wild type p53 promotes
apoptosis. Thus whether a given cell responds to the activation ofwild type p53 by
growth arrest or apoptosis is determined by the status of the pRb family. If these
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proteins are functional the cell will arrest and may re-enter the cell cycle when p53
activity is normal. Conversely, in the absence of functional pRb the cell will fail to arrest
and enter apoptosis (Haffner 1995).
A possible function of p53 may be to provide a reversible G1 growth arrest to allow
for DNA repair prior to subsequent rounds of replicative DNA synthesis. This
explanation is somewhat contradicted by the fact that some p53 blocked cells apoptose
or senesce (Cox 1995). In addition over expression of p53 can lead to repression of
many genes probably through interaction with components of the basal transcription
machinery (Haffner 1995). Mitotic cells can proceed normally in the absence of p53
since mice that are p53 null develop fully (Cox 1995). The presence of functional p53
can restrict tumour development by promoting apoptosis of neoplastic cells. The same
tumours in p53 null mice grow aggressively underscoring the tumour suppressing
properties of p53 (Symonds 1994).
As described above wild type p53 is necessary for G1 arrest in response to certain
types ofDNA damage although this can be circumvented by activated oncogenes (e.g.
ras and HPV E7) (Cox 1995). Humans, who are heterozygous for the wild type allele
ofp53 develop cancer with a very high frequency, greater than 90% and often at an
early age (Levine 1997). p53 mutations are found in 50-55% of all human cancers
(Hollstein 1994) The timing ofp53 somatic mutations in human cancers apparently
depends on tumour type. In colorectal cancerp53 mutation is a late event. In skin
cancers, by contrast, p53 mutation appears early in pre-malignant lesions (Levine
1997).
Tumours with allelic deletion of 17p frequently contain point mutations that results
in amino acid substitutions in the retained allele. These mutations are not exclusively
confined to tumours with allelic deletion (Lamb 1986). Some 98% ofp53 mutations
occurring in human tumours represent somatically acquired mutations (Hollstein 1991)
and 98% of substitution mutations occur in the region codons 110 - 307 contained in
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exons 5-9 which is the most evolutionary conserved (Hollstein 1991). Analysis ofp53
mutations identifies several codons at which exceptionally high numbers of tumour
mutations are clustered (hot spots). When mutations are examined separately by cancer
type clear differences can be identified in the position of the hot spots and in the
frequency of transitions and transversions. G:C to A:T transitions contribute the
majority of colon cancer mutations (79%) and most occur at CpG dinucleotides. More
than 50% of colon tumour transition mutations are at three CpG hot spot 175, 248 and
273 (Hollstein 1991). More rarely mutations produce deletions or chain terminations in
thep53 gene (Levine 1997).
These genetic changes inp53 in cancer cells most commonly result in a missense
mutation in one allele which produces a faulty protein. This faulty protein is then
observed at high concentrations in these cells (Levine 1997). Mutations inp53 gene
occur during the process of tumourigenesis may cause tumour progression by a
dominant negative effect. The dominant negative effect may be mediated by binding of
the mutant p53 product to the wild type product creating an inactive oligomeric
complex. Further loss of control can be expected when the wild type allele is deleted
leaving the cell with only the mutant allele (Lamb 1986).
More than 90% ofmissense mutations lie in the sequence specific DNA binding
domain. Mutations in amino acids arginine 248 and arginine 273 are the most frequently
altered residues and result in defective contacts with DNA and the loss of the ability of
p53 to act as a transcription factor. Other sites for mutation alter the structural
conformation of this domain and can be detected by the monoclonal antibodies (Levine
1997). Residues targeted by common hot spot mutations are either engaged directly in
DNA contacts or else play pivotal roles in stabilising the proper structure of the binding
domain. (Cho 1994) supporting the argument that the loss of sequence specific DNA
binding is selected far more strongly in tumour cells. (Haffner 1995)
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Tumours with the wild type p53 often respond well to chemotherapy e.g.
teratocarcinomas via p53 mediated apoptosis. Other cancers which frequently contain
p53 mutations e.g. colorectal cancer respond poorly to chemotherapy. p53 mutations
have been reported to result in shorter disease free survival and lower total survival of
patients (Aas 1996)
iii)APC
APC the gene associated with FAP was initially located by linkage analysis to
chromosome 5q21-22 (Bodmer 1987) and subsequent cloning studies identified the
gene (Groden 1991; Kinzler 1991). The coding region of the gene spans 8.5 Kb and has
fifteen exons, the largest being the fifteenth which accounts for 3/4 of the coding region
(Groden 1991; Kinzler 1991). Over 95% ofmutations in APC lead to chain termination
resulting in the expression of truncated proteins, the consistent deletion of the carboxy-
terminal suggests that important growth suppressive activity resides in this portion of
the protein. Germ line mutations are distributed in the 5' portion of the gene with two
hot spots at codons 1061 and 1309 accounting for 35% of the total (Polakis 1995).
Somatic mutations exhibit definite grouping between codons 1286 and 1513 termed the
mutation cluster region (MCR) (Miyoshi 1992). The finding that greater than 94% of
somatic mutations found in FAP tumours are in the MCR suggests there is a selective
pressure for at least one allele to be mutated in the MCR (Polakis 1995 Miyaki 1994).
Further evidence to suggest that the position of the mutation in APC is important
comes from the recognition that different mutations produce different FAP phenotypes,
and the phenotype can be determined from the position of the mutation (reviewed in
Cunningham 1996 and Polakis 1995). Individuals with mutations 5' to codon 157 have
an attenuated phenotype with few polyps. The presence of the extracolonic feature
congenital hypertrophy of the retinal pigment epithelium (CHRPE) is also dependent on
the position of the APC mutation, retinal lesions are almost always absent if the
mutation is 5' to exon 9 and present if 3' to exon 9 (Olschwang 1993). This suggests
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the expressed mutant protein has some residual interfering function that influences the
presence ofCHRPE and similar residual function could account for the neoplastic
effects of expressed mutant protein (Polakis 1995).
The APC gene encodes for a 300 kilodalton cytoplasmic protein (Groden 1991)
which can be divided into two domains, the amino terminal domain which represents a
quarter of the protein is leucine rich and shows sequence similarities to myosins,
intermediate filament proteins and Drosophila armadillo protein. The carboxy terminal
three quarters is serine rich with no discernible homology to known proteins (Kinzler
1991). Two regions in the N-terminus show a coiled coil structure through which it
homodimerizes (Kinzler 1991 Su 1993). APC interacts with several different proteins
including fl-catenin, y-catenin, tubulin, hDLG, and glycogen synthase kinase-3b (GSK-
3b) (Morin 1997).
The function ofAPC remains unclear, although it has been implicated in cell
adhesion. APC binds directly with B and y catenins, but not E-cadherin, which are all
involved in adherins cell junctions (Su 1993; Rubinfeld 1993) and multiple B-catenin
binding sites have been identified (Polakis 1995; Morin 1997). Thus APC may serve as
a down stream target for signaling by B-catenin or may competitively bind B-catenin
regulating its action on another downstream target. Wild type APC has been shown to
down regulate B-catenin, mutant protein truncated at the MCR is also capable of
binding B-catenin but does not down regulate its action (Polakis 1995). Expression of
-NH2 deleted B-catenin in epithelial cell models results in loss of cell morphology and
the mutated B-catenin can be shown to co-localise to APC protein clusters (Pollack
1997). B-catenin also functions as a transcriptional activator when complexed with
members of the T-cell transcription factor family (Tcf) (Molenaar 1996). Wild type
APC can suppress signaling by the B-catenin-Tcf complex (Korinek 1997) however the
protein products ofmutant APC genes present in colorectal cancer are defective in this
activity suggesting regulation of B-catenin is central to APC s tumour suppressive effect
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and this can be circumvented by mutations in APC (or in the B-catenin gene) (Morin
1997). APC may, therefore, exist in equilibrium with B-catenin and E-cadherin and
mutations may alter this equilibrium causing loss of growth control resulting in
adenoma formation.
The APC protein localises to the ends of the microtubules that extend in to actively
migrating regions of epithelial cell membranes. APC levels increase at the crypt / villus
boundary where migration is required for enterocytes to exit from the crypt, suggesting
APC protein plays a role in directed cell migration (Nathke 1996). This function of
APC would appear to regulated by binding ofB-catenin. Wild type B-catenin binds
transiently to APC at the microtubule complex, however mutant B-catenin deficient in
its N-terminus which contains the a-catenin and E-cadherin binding sites forms
abnormally stable complexes with APC resulting in inhibition of cell migration. In the
presence of normal cell proliferation stimuli this results in cell aggregates in vitro (i.e.
polyps in vivo) (Pollack 1997). Given the size ofAPC and the number of proteins with
which it interacts, it suggests that APC serves to integrate the signals from a variety of
sources and transmit them to the nucleus by the B-catenin / Tcf complexes (Kinzler
1996).
These observations would support the postulation that APC mutation is required for
initiation of adenoma formation and subsequent carcinogenesis. When one functional
copy ofAPC is present this can act as a gatekeeper maintaining a constant cell
population, mutation in the gatekeeper gene leads to an imbalance in cell proliferation
resulting in net proliferation (Kinzler 1996). APC mutations have been detected in very
small adenomas and their precursors, aberrant crypt foci, suggesting initiation of
adenoma formation requires an inactivating mutation ofboth APC alleles (Jen 1994).
Also mutations inp53 and Ki-ras without the presence ofAPC mutations do not appear
to produce neoplastic cells (Kinzler 1996).
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iv) Mismatch Repair Genes
The syndrome ofHereditary Non-Polyposis Colon Cancer (HNPCC) is characterised
by young patients with right sided colonic cancers (Lynch 1993). Linkage analysis has
proved a genetically determined form ofHNPCC (Peltomaki 1993). With colorectal
cancer being such a common disease establishing a true genetic link rather than chance
clusterings for HNPCC required the analysis of large kindreds. Analysis of two large
kindreds with the examination of over 300 microsatellite markers identified an HNPCC
gene localising to chromosome 2pl5-16 (four point lod scores of 6.47 and 6.01 for the
two kindreds) (Peltomaki 1993). Other work identified a second HNPCC gene on
chromosome 3p21 (Lindblom 1993). Loss of heterozygosity (LOH) analysis of the
HNPCC gene on chromosome 2pl6 surprisingly showed this gene was not deleted in
any of 14 HNPCC cancers and only in one sporadic cancer. (Aaltonen 1993).
Furthermore the majority ofHNPCC tumours demonstrated shifts in the electrophoretic
mobility of (CA)n and (CAG)n microsatellite repeat sequences (microsatellite
instability).
Formal analysis of 5 loci in 14 HNPCC tumours revealed 11 (79%) cases in which
two or more loci demonstrated mobility shifts (Aaltonen 1993). Such cancers are said
to demonstrate a replication error (RER+) phenotype or microsatellite instability
(MIN). This phenomenon is not noted in other normal tissues of patients with RER+
cancers (Thibodeau 1993) suggesting that it is this replication error occurs during the
cancer development and that there is some underlying cause for the RER+ phenotype
which might predispose cancer formation. This does not appear to be the case with
sporadic colorectal cancer. Analysis of 46 sporadic cancers identified an RER+
phenotype in only 6 cases (13%) (Aaltonen 1993). In common with HNPCC tumours
sporadic RER+ cancers tend to be right sided and are frequently diploid (Aaltonen
1993) suggesting either a common mechanism of tumourigenesis or that these sporadic
cases represent previously undetected HNPCC kindreds.
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Errors in replication were initially recognised as novel alleles in non-coding regions
ofDNA which contain dinucleotide repeats (microsatellites) (Ionov 1993). Mutations in
the yeast genes pmsl, mlhl and msh2 involved in mismatch repair also lead to
microsatellite instability similar to that identified in RER+ colorectal cancers (Strand
1993) suggesting mutations in human homologues of these genes could be involved in
HNPCC tumourigenesis. The human homologue of the yeast mismatch repair gene
msh2, hMSH2 localises to chromosome 2p22-21 (Fishel 1993) close to the locus used
for linkage analysis of the HNPCC kindreds confirming the involvement of human
mismatch repair genes in HNPCC. To date five mismatch repair genes have been
identified, by homology to bacterial and yeast mismatch repair genes, hMSH2 (Fishel
1993; Leach 1993), hMLHl (Papadopoulos 1994), hPMSl and hPMS2 (Nicolaides
1994) and GTBP (Palombo 1995). These gene products are responsible for DNA
replication fidelity in humans. Mutations in these genes lead to an unstable genome in
which errors in DNA replication frequently occur (Parsons 1993). Restoration ofMMR
function to cell lines deficient in MLH1 completely reverses replication error (Koi
1994). An RER+ phenotype has been demonstrated in 92% ofHNPCC kindreds and
MMR gene mutations can be identified in 70% of these (Liu 1996b). Of these
mutations hMSH2 mutations account for 31%, hMLHl 33%, hPMSl 2% , hPMS2 4%
and GTBP 0%. hMSH2 and GTBP form a heterodimer but only hMSH2 is commonly
mutated, similarly hMLHl and hPMS2 heterodimerise yet only hMLHl is commonly
mutated (Liu 1996b). Some ethnic variation has also been noted. Over 90% ofMMR
mutations in Finnish families fulfilling the Amsterdam criteria were due to hMLHl
suggesting a significant founder effect (Nystrom-Lahti 1996). Rather surprisingly
hMSH2 and hMLHl mutations were identified in only 25% ofHNPCC kindreds in the
Eastern United States (Weber 1997).
Some 86-92% of tumours from HNPCC patients are RER+ (Aaltonen 1994; Liu
1996b), contrast 16% of sporadic colorectal cancer. Additionally 57% of adenomas
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from HNPCC patients are RER+ contrast 3% of sporadic adenomas suggesting the
involvement of mismatch repair in the pre-malignant stage ofHNPCC cancers.
Interestingly in some HNPCC patients with multiple adenomata not all were RER+.
This suggests the RER+ phenotype is not necessary for adenoma formation but that
mismatch repair accelerates the adenoma - carcinoma progression (Aaltonen 1994),
accounting for the younger age ofHNPCC patients. Whilst the majority ofHNPCC
patients have germline mutations in one of the mismatch repair genes (Liu 1996b) only
one in ten sporadic colorectal cancers demonstrating RER+ have germline mutations
(Liu 1995). Furthermore, only 3/7 sporadic RER+ colorectal cancers had detectable
mutations in the known MMR genes. This suggests a different mechanism of
tumorigenesis in such cancers or that these cancers have mutations in previously
undiscovered MMR genes. All tumours with identifiable MMR gene mutations in this
study had mutations in both alleles fulfilling Knudsons criteria for a tumour suppressor
gene (Liu 1995).
Of the 10-17% of sporadic cancers that demonstrate MIN (Bubb 1996; Ionov 1993)
hMSH2 alterations are found in 61% however only 4% have exonic mutations (Bubb
1996). Mutations in the mismatch repair genes are often indirectly detected by the
identification ofMIN. Replication error is not confined to non-coding regions of the
genome and errors can conceivably occur in important oncogenes or tumour suppressor
genes leading to tumour progression. Mutation rates in cells with MMR deficiency are
two to three orders ofmagnitude higher than normal cells (Eshleman 1995). Hence the
mutations in the HNPCC genes are not directly carcinogenic but act to accelerate the
accumulation of other specific mutations required for colorectal carcinogenesis (Kinzler
1996).
Transforming Growth Factor Beta Receptor II Gene
Genes that contain repeated nucleotide sequences within their reading frame would
be an obvious target for mutations due to mismatch repair. One such example is the
48
Transforming Growth Factor fi Receptor II (TGFfi RIP) gene which has a 10 bp
polyadenine repeat (A10) within exon 3 (Lu 1996). Transforming growth factor 13 I
(TGF13I) is a potent inhibitor of cell proliferation and many tumour cell lines have lost
their response to TGFBI suggesting its loss of action may be important in neoplastic
transformation (Alexandrow 1995). TGFBI acts through a receptor consisting of three
components ofwhich TGFB RII forms a part. Inactivation of either TGFB receptor I or
TGFB RII results in TGFBI resistance (Wrana 1994). Frame shift mutations due to 1 or
2 bp insertions or deletions, suggestive of replication error, have been found within the
Am repeat in the TGFfi RII gene in 90% of colorectal cancers or related cell lines with
microsatellite instability (Parsons 1995b). This supports the idea that TGFfiRII is an
important target of inactivation in mismatch repair deficient tumours. Similar findings
have been found in other genes with repeated sequences in their coding region for
example, Insulin-like growth factor II receptor (IGFIIR) gene contains an 8 bp
polyguanine repeat. IGFIIR binds TGFBI and is essential for TGFBI activation. IGFIIR
also antagonises the growth stimulatory action of Insulin-like growth factor II; frame
shift mutations in the polyguanine segment have been identified in 12.5% ofHNPCC
tumours and 9% of sporadic RER+ tumours. Interestingly there is an inverse
relationship with TGFfi RII mutations, RER+ tumours either have a TGFfiRII mutation
or an IGFIIR mutation but not both (Souza 1996). The BAXgene also contains an 8 bp
polyguanine segment in which showed frame shift mutations in 50% ofMIN colorectal
cancers (Rampino 1997).
The practicality of a molecular screening approach will depend on the chromosomal
sites chosen for analysis. Although it has been shown that any clonal expansion of
genetically modified site is of value in screening for neoplasia (Mao 1994) in colorectal
cancer there are additional advantages in studying changes in specific genes as these can
have distinct biological significance (Hamilton 1992). As detailed in the preceding
sections APC is the hallmark of almost all colorectal neoplasms, benign and malignant.
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Ki-ras mutations are found in 45% of carcinomas and the larger dysplastic adenomas.
Mutations inp53 are found in 50% of carcinomas and very few adenomas. Finally
TGFJ3 RIImutations are associated with the majority of cancers due to mismatch repair
deficiency. Thus it is anticipated that analysis of these four important sites ofmutation
in colorectal cancer would be expected to identify the majority of cases.
1.6 Telomerase activity in neoplastic tissues
Most cells that can divide in vivo cannot do so indefinitely. The process that limits
the proliferative potential of cells is termed cellular or replicative senescence.
Replicative senescence is especially stringent in human cells and most proliferatively
competent mammalian cells senesce. Somatic cells acquire this finite replication
sometime during embryonic development through mechanisms which remain unclear
(Campisi 1997). Senescence represents a phenotype in which cells although
proliferatively arrested, remain biochemically active and viable for long periods of time
(Wynford- Thomas 1997). There are 3 notable exceptions to senescence, germ cells,
stem cells and malignant tumours. Replicative senescence can act as a tumour
suppressive mechanism and tumour cells often acquire mutations that allow them to
overcome the proliferative constraints of senescence. A number ofwell recognised
proto-oncogenes and viral oncogenes appear to act by allowing cells to escape from
replicative senescence (e.g. C-MYC and SV40 virus large T antigen gene). Also the
tumour suppressor genesp53 and RB are essential for maintaining senescence
(summarised in Campisi 1997). In fibroblasts senescence can be induced by gene
products known to inhibit cell proliferation such as p21WAF1 and pl6INK4a. Senescence
can be abrogated by mutations inp53 and pRb (Wynford- Thomas 1997). Escape from
cellular senescence predisposes a cell to neoplastic conversion (Oshimura 1997). It has
been proposed that cellular senescence is controlled by genes which are activated or
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have functions which become evident at the end of the proliferative life span of the cell
(Sugaware 1990). Hybrids of normal and tumour cells senesce suggest the genetic
information contained in the normal cell can correct defects in the tumour cell. Single
chromosome transfer has shown putative senescence genes on at least 10 chromosomes
suggesting a multiple pathway mechanism. A number of defects by which a cell can
escape senescence and proceed to neoplasia are therefore possible (Oshimura 1997).
The mechanism by which cells sense the number of divisions they have completed
and enter senescence depends in part on the length of the telomeres. Telomeres are the
ends of linear chromosomes consisting in humans of the repetitive sequence TTAGGG.
Telomeres serve to maintain the stability of the genome by protecting against
chromosome fusions, translocations and non-dysjunctions.
DNA polymerases are unidirectional and require a labile primer, thus each round of
replication leaves some 3' bases at the telomere unreplicated hence for most cells
telomeres shorten with each replication. Analysis of telomere length as a function of age
or cell division number shows that telomeres gradually shorten with age or cell division
number. It is thought that this gradual loss of telomeric DNA could lead to
chromosomal instability and contribute to aging and senescence. In germ cells the
average telomere length is maintained at around 5 - 10 kb (Blackburn 1991). Germ cells
do not undergo replicative senescence and differ from most other cells in that they
exhibit telomerase activity (Campisi 1997).
Telomerase is a multimeric ribonuclear enzyme that adds telomeric repeats to
chromosome ends de novo (Campisi 1997) maintaining the length of the telomere.
Telomerase synthesizes the G-rich strand of telomeres in a 5' to 3' direction. The
reaction does require ATP and both the RNA and protein components are essential for
the reaction. The telomerase RNAs of lower organisms have been shown to contain
sequences that are complementary to their DNA telomeric repeats. It would appear that
this complementary RNA acts as a template by which telomerase synthesizes the G-rich
strand. This is confirmed by the finding that mutated RNAs in the complementary
sequence result in telomeres elongated by the new mutated sequence (Blackburn 1991).
In cell lines and cancers exhibiting telomerase activity the telomere length is stabilised
rather than continuing to elongate indefinitely. This suggests that a regulating
mechanism exists for limiting telomere elongation by telomerase (Blackburn 1991;
Cooper 1997; van Steensel 1997). Over expression of telomerase with mutated RNA in
Tetrahymena can cause a dominant negative phenotype leading to telomerase
shortening (Blackburn 1991). Human telomeric-repeat binding factor (TRF1) is a
duplex telomeric TTAGGG repeat binding protein that is associated with human and
mouse telomeres in interphase and mitosis. TRF1 over expression in a cell with
telomerase activity and stable telomeres results in a gradual progressive shortening of
the telomere. Mutant TRF1 that lacks a DNA binding motif demonstrates a dominant
negative effect leading to telomere elongation. These findings suggest that TRF1
modulates telomere length through a negative feed back effect. Interestingly the DNA
binding motif shows close homology to the proto-oncogene MYB (van Steensel 1997).
In further support of a negative feedback regulation a telomere binding protein Tazlp
(from the fission yeast Schizosacchromycespombe) shares homology with the MYB
DNA binding domain of TRF1. Disruption of its gene tazl+ leads to massive increase
in telomere length (Cooper 1997) suggesting these telomere binding proteins may be
negative regulators of telomerase or may protect against telomerase independent
pathways of telomere elongation. In S. cerevisiae the telomere binding protein Raplp
also shares homology with the MYB domain ofTRF1. Telomere length in S. cerevisiae
depends on the number ofRaplp molecules bound to the telomere (Marcand 1997).
Peak and average telomere length have been shown to be shorter in cancers when
compared adjacent normal tissue (Engelhardt 1997) suggesting the telomerase / TRF1
feed back mechanism may have some influence in tumourigenesis.
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The G rich strand (G-strand) is always located at the 3' end of the chromosome and
it is thought that the G-strand overhangs its complementary strand and is thus single
stranded. There are a number of proteins that avidly bind to single stranded G-strands,
which itself can also form complex secondary structures in vitro, whether such
structures exist in vivo and their possible function remain to be elucidated (Wellinger
1997).
Telomerase activity is not found in somatic cells (Engelhardt 1997) but its activity
has been noted in cancer cell lines and tumours suggesting it may play a role in
tumourigenesis (Campisi 1997). Whether telomerase activity in cancers represents a
real return to telomerase expression by the cancer cells or is simply due to an
enrichment in stem-like cells that are known to have telomerase activity is not
understood. However, semiquantitative studies have shown that the amount of
telomerase activity depends on the proportion of tumour cells in the examined specimen
(Engelhardt 1997). A survey of 3500 cancers and cancer cell lines has shown
telomerase activity is wide spread in neoplastic tissue. In colorectal cancers and cell
lines telomerase activity can be detected in 89% of carcinomas and 45% of adenomas
(Shay 1997). Other research would suggest this proportion is even higher at around
95% (Odogwu 1997). Telomerase activity has been identified in histologically normal
tissue adjacent to cancers and in premalignant lesions suggesting telomerase activity in
these tissues is due to the presence of previously undetected cells (Kim 1997). The
detection of telomerase activity may therefore represent a ubiquitous and early tumour
marker that could be used for screening.
1.7 Mutational mosaicism
As described in section 1.5.4 individuals with mutations in the mismatch repair genes
have an increased cancer susceptibility. Recent work has shown that greater than 50%
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of individuals who develop colorectal cancer at an atypically early age (less than 35
years of age) have germ-line mutations in the mismatch repair genes (Liu 1996). It is
widely assumed that these individuals accumulate mutations in genes essential to
colorectal cancer development exclusively in the founder cells of tumours or their
neoplastic clones (Kinzler 1996). Certain individuals from HNPCC families with
apparently heterozygous MMR gene mutations show constitutionally deficient MMR
which can induce alterations at repeat sequences in non-neoplastic tissues (Parsons
1995). This raises the possibility that individuals bearing germ-line mutations in
mismatch repair genes may undergo somatic mutations in cancer genes at an early stage
in embryonic development and that cells bearing these mutations may become
distributed into a variety of tissues. Such individuals would thus be genetic mosaics
with some cells having an enhanced cancer susceptibility scattered amongst normal cells
(Dunlop 1996b). Support for this theory comes from the fact that certain patients with
attenuated extracolonic manifestations ofFAP, such as mandibular osteomas and
congenital hypertrophy of the retinal pigment epithelium (CHRPE), but with non-
polyposis cancer, are significantly more likely to have right sided RER+ cancers. This
suggests an underlying MMR defect in such individuals (Dunlop 1996). One
interpretation of this observation is that such individuals have a germline deficiency in
MMR. and an early acquired moasicism in APC. APC mosaicism in humans has been
reported (Mandl 1994). Cancers associated with mismatch repair gene defects tend to
display a constellation of clinical and molecular pathological features including MIN
(Lothe 1993; Kim 1994). RER+ cancers account for 15 - 20% of conventional late
onset colorectal cancer (Lothe 1993; Thibodeau 1993; Aaltonen 1994). Interestingly
germline defects in the mismatch repair genes are seldom found in patients with late
onset disease (Liu 1995; Liu 1996b). At present it is not clear whether such patients
carry constitutional mutations in hitherto undiscovered MMR genes, or, bear mutations
exclusively in the founder cells of their cancers or are limited mosaics for certain cancer
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predisposing mutations such as APC. whole gut lavage fluid may provide a method by
which the entire colonic mucosa can be sampled and may be useful in determining the
possibility ofAPC mosaicism in microscopically normal mucosa.
1.8 Aims
This thesis had several aims. Firstly in recognising the difficulties in using stool for
DNA mutational analysis the suitability ofwhole gut lavage fluid for DNA extraction
and PCR analysis was evaluated. Secondly where all previous studies examining cancer
mutations in stool samples had confined their search to one gene it is clear that several
mutations sites must be interrogated to improve overall sensitivity. As a proofof
principle the systematic analysis of 4 genes commonly mutated in colorectal cancer
(namely Ki-ras codon 12, p53 codon 248, APC mutation cluster region and TGFfi RII)
was initially undertaken.
In a related line ofwork while telomerase activity can be detected in laboratory
lavage samples from colorectal cancer specimens, this activity has not been detected in
clinically obtained samples. Preliminary work to try and detect telomerase activity in
whole gut lavage fluid was undertaken.
Successful development of techniques to detect mutations in whole gut lavage fluid
would provide a useful research method by which to examine mechanisms of colorectal
carcinogenesis particularly in high risk individuals. In high risk individuals with a
macroscopically normal bowel random colonic biopsy for genetic analysis at
colonoscopy is of little value. Whole gut lavage may provide a method by which the
whole colonic mucosa could be sampled. In this way it may be possible to identify pre-
malignant mutations in high risk individuals in whole gut lavage. One obvious candidate
would be APC. With successful detection ofAPC mutations in whole gut lavage fluid in
known cancer patients the final aim of this thesis was to apply these tests to whole gut
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lavage fluid obtained from asymptomatic high risk individuals to try and further
elucidate the mechanism of tumorigenesis in these subjects.
2. Materials and methods
2.1 Whole gut lavagefluid
Whole gut lavage fluid was obtained preoperatively by standard methods, developed
in the GI laboratory Western General Hospital Edinburgh (Choudari 1993) from
patients with known colorectal cancer. Local ethical approval was obtained and each
patient gave informed consent. Polyethylene glycol in the form of a balanced electrolyte
solution "Klean Prep" (Norgine Ltd., Harefield, Middlesex, UK.) was administered
orally at a rate of 250 ml every 15 minutes until the effluent passed per rectum was
clear of particulate matter. A 100 ml sample was then collected for DNA extraction.
The majority of samples were obtained from hospital inpatients, but in six patients
sample collection was performed as an out patient procedure. Here additional samples
were processed and stored according to laboratory protocol. Lavage fluid was clarified
in a centrifuge at 2500 rpm for 5 min. To 3 x 1.5 ml aliquots ofunfiltred and
unprocessed lavage fluid 30 pi of 2% sodium azide was added and then stored at -70°C.
A 10 ml aliquot of lavage fluid was filtered through Whatman GF/A 12.5 filter paper. A
second 10 ml aliquot was removed from the unfiltred lavage fluid. To 5 ml of each
aliquot 0.5 ml of 0.1% of soya bean trypsin inhibitor, 0.28 ml of 0.1M disodium
ethylene diamine tetraacetic acid (pH 8.0), 0.12 ml of 0.3M
phenylmethylsulphonylfluiride and 0.06 ml of 2% sodium azide were added. The
mixtures were incubated at room temperature for two minutes before the addition of
0.3 ml of new born calf serum. For each processed sample (filtered and unfiltered) 1.5
ml aliquots were dispensed and stored at -70°C.
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2.2 Cellular analysis ofwhole gut lavagefluid
Cell separation was undertaken by density gradient centrifugation adapted from
methods developed in the GI laboratory at the Western General Hospital Edinburgh
(Handy 1995).
Discontinuous Elution gradients
Twenty-five ml ofwhole gut lavage fluid was coarsely filtered using surgical gauze
then centrifuged at 850 g for 10 minutes. The supernatant was discarded and the cell
pellet resuspended in 5 ml ofHanks' balanced salt solution (Sigma Chemical Co. Ltd.,
Poole, UK). This was layered on top of a discontinuous density gradient using
Histopaque 1119 and 1077 (Sigma) and centrifuged at 700 g for 30 minutes. Resulting
cell layers were harvested separately washed with Hanks' balanced salt solution and
used for cell count or preparation of cytospin slides.
Continuous elution gradients
The discontinuous gradient was further refined by preparing a continuous density
gradient using a gradient mixer with 5 ml ofHistopaque 1119 and 1077. The mixture
was siphoned into the centrifuge tube at a constant rate (2 ml / min.) using a peristaltic
pump. (The refractive index RI of samples taken at intervals from a control gradient
when prepared as outlined above demonstrated a linear relationship to the proportions
ofHistopaque 1119 and 1077. This confirmed even and satisfactory mixing of the
buffers to produce a continuous elution gradient.) Whole gut lavage samples were
layered on the top of continuous gradients and processed in an identical manner to the
discontinuous gradient. After cell separation the gradient was siphoned off again using
the peristaltic pump at the same rate in to 1 ml aliquots. Cell counts were performed




These were made using a haemocytometer in the standard way. A 5 gil drop of each
sample was placed on the haemocytometer slide and covered with a cover slip to
produce an even film. The slide was then examined under x 100 magnification and cells
counted. For the discontinuous elution gradient cell counts were made for each cell
layer. For the continuous gradients each 1 ml aliquot was analysed. Average cell counts
were recorded from 4 observations for each layer or aliquot.
Cytospin preparation
Duplicate slides were made using 50pl and 100pi aliquots of the two separate cell
layers for samples using a discontinuous gradient and for each aliquot that contained
cells when the continuous gradient was used. The samples were centrifuged at 90 g for
10 minutes, air dried and fixed in 10% formalin before Haematoxylin and Eosin
staining. Histological examination was performed under the supervision of a Consultant
Histopathologist (Dr. M. J. Arends).
2.3 DNA extraction
From paraffin sections
Normal and tumour control DNA samples were obtained from paraffin blocks of the
surgically resected specimen. Three 10 pm sections were cut using a microtome, placed
in a sterile 1.5 ml eppendorf tube and stored at 4°C until required. DNA was extracted
using standard methods (Levi 1991). Briefly 400 pi of lysis buffer (10 mM Tris, pH 8.3,
50 mM KC1, 0.45% Tween 20, 2.5 mM MgCl2) was added to each eppendorf tube
along with Proteinase K (0.5 mg/ml) and incubated at 55°C for twenty-four hours then
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boiled for 20 minutes, 100|j.l aliquots of the resulting supernatant were stored at -20°C
until required and 3-5 pi aliquots were used for PCR analysis.
From frozen tissue
In a dedicated class II biological safety cabinet a small portion of the tissue (0.3
3 •
mm ) was diced and place in a sterile 1.5 ml. eppendorf tube to which 500 pi of TE-9
SDS (500 mM Tris pH 8.0, 20 mM EDTA, 10 mM NaCl, 1% SDS) was added along
with proteinase K (0.5 mg/ml) and incubated for 48 hours at 48°C vortexing
intermittently. An equal volume ofTE (10 mM Tris pH 8.0, 1 mM EDTA) saturated
phenol was added, mixed thoroughly and the phases separated using a microfuge
(13,000 rpm for 2 minutes). The aqueous phase was then removed to a clean tube and
another separation with TE saturated phenol undertaken. The aqueous phase was then
mixed with an equal volume of chloroform / iso-amyl alcohol (ratio 24:1) and further
separation in the microfuge at 13,000 rpm for 2 minutes. Once again the aqueous phase
was removed to a clean tube and the DNA precipitated by adding 0.25 ml of 7.5M
ammonium acetate and 1 ml of cold absolute ethanol and left over night at -20°C. The
precipitate was pelleted using the microfuge and vacuum dried before resuspension in
0.25 ml ofTE buffer.
From whole gut lavage fluid
Several methods ofDNA extraction from whole gut lavage fluid were evaluated.
Successful DNA extraction was determined by subsequent PCR amplification of the
mitochondrial gene cytochrome b (Smith-Ravin 1995). The best method was adapted
from the method used by Smith-Ravin et al. (Smith-Ravin 1995) to extract DNA from
stool samples. To 100 ml whole gut lavage fluid, in 4 aliquots of 25 ml, lysis buffer was
added to a final concentration of 10 mM Tris, 1 mM EDTA, 0.5% SDS, pH 7.5 within
15 minutes of sample collection and incubated at room temperature for 30 minutes. The
samples were clarified by centrifugation at 1500 rpm using a Sorvall RT 6000D
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centrifuge at 5°C. The supernatant was removed from each sample and extracted with
an equal volume of TE saturated phenol in a clean tube. The supernatant was again
removed to a clean tube and the DNA was precipitated with an equal volume of cold
isopropanol. This precipitate was pelleted in the centrifuge at 3000 rpm for 30 minutes
and the supernatant discarded. The resulting pellet was dried before resuspension in 500
pi - 1 ml ofTE and digested with proteinase K (0.5 mg/ml) at 48°C for 24 hours. Two
to three phenol / chloroform extractions as required followed by ethanol precipitation
were then undertaken. Finally the resulting pellet was dissolved in 50 - 100 pi of TE
followed by further purification in GeneClean Spin Columns (Bio 101, Inc., Vista, CA,
USA.) according to the manufacturer's protocol.
DNA concentration measurement by spectroscopy
The concentration ofDNA samples was determined by measuring the absorption of
the sample at 260 nm and calculated using the following formula.
[DNA] = 50Dx
Where 50 represents a standard correction factor for double stranded DNA
D = the adsorption at 260 nm
x represents a correction for dilution of the sample (usually 500)
DNA concentration measurement by UV fluorescence
Aliquots (1 pi) of standard DNA concentrations (10 pg/ml to 500 pg/ml) where
placed on to gels containing ethidium bromide (0.5 mg/ml). Close to these where
placed lpl aliquots ofDNA solutions from whole gut lavage fluid samples. These were
left for 10 minutes to be absorbed into the gel. The gels were then visualised using
video equipment under UV light in a light tight chamber. The standard DNA
concentrations were used to construct a standard curve and the whole gut lavage fluid
DNA concentrations were then estimated using quantitative software (Biorad
Molecular Analyst) and by eye.
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2.4 Polymerase Chain Reaction
Primers
Unless otherwise stated all primer sequences used were as published in the literature
and are referenced in the relevant section. Stocks were obtained from commercial
companies (Cruachem Ltd., Glasgow, Scotland, UK.; Oswell DNA Service, University
of Southampton, Southampton, UK.) and stored at -20°C. Aliquots for PCR and
sequencing were diluted to a concentration of 10 mM and stored separately from the
stock solutions at -20°C. Additional primers were designed from known sequences
using the "Primer" shareware program available on the Internet (Whitehead Institute,
Cambridge, Massachucetts, USA.)
Optimisation of reaction conditions
All reactions were performed using Taq DNA polymerase (Gibco BRL, Life
Technologies, Paisley, Scotland, UK.). Reactions were set up in a separate dedicated
Class II biological safety cabinet and any dilution was performed with autoclaved
deionised water. To avoid cross contamination DNA was added to prepared reaction
mixtures in a second separate dedicated horizontal laminar flow hood. All reactions
(unless otherwise stated) were prepared according to the manufacturer's protocol and
contained lOx reaction buffer diluted to a final concentration of 20 mM Tris-HCl, (pH
8.4) and 50 mM KC1. A 10 mM nucleotide mixture was diluted to give a final
concentration of 0.2 mM of each nucleotide. For reactions using DNA from paraffin
sections a 1% W-l detergent was added to a final concentration of 0.05% (v/v). Each
reaction contained 2.5 units of Taq DNA polymerase. Initial PCR optimisation was
2_j_
performed by varying Mg and primer concentrations. A 50 mM MgC^ solution was
added in lpl aliquots to vary the final concentration from 1.0 to 2.5 mM. Each primer
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was made up to a lOpM concentration and added in 2.5pi aliquots to vary the final
concentration between 0.25 and 1 pM. Between 5 and 200 ng of template DNA (in a
volumes of 1 - 5pi were added. The resultant mixtures were diluted using autoclaved
distilled water to a final reaction volume of 50 pi. Evaporation was prevented by a
25 pi mineral oil overlay. Reactions were performed in a Hybaid Omnigene
thermocycler. For reactions that required further optimisation the annealing
temperature (Tm) was also varied by ± 1°C increments. The end point for optimisation
was a single PCR product seen on agarose gel electrophoresis with ethidium bromide
staining. Negative control reactions containing no DNA were included in every
reaction. Individual reaction conditions are detailed in the appendix. To confirm
successful amplification all PCR products were routinely resolved on 1-3% agarose
gels, depending on product size. A 1 Kb molecular weight marker was added to one
lane and each gel run at constant voltage (125V) with lx TBE buffer (Tris Borate
EDTA). Ethidium Bromide (1 mg/ml) was added to each gel and products were
visualised under UV light.
Ki-ras codon 12 enriched PCR
The point mutations at Ki-ras Codon 12 and p53 codon 248 were analysed using an
enriched PCR strategy (Kahn 1991; Tobi 1994). For the detection ofKi-ras codon 12
mutations the 5' primer was modified to contain a G to C substitution at the first base
pair position of codon 11 which in turn produces BstNI restriction enzyme site
(5'..CCTGG..3') overlapping the first two base pairs of codon 12 (Fig 2.1). Wild type
product will therefore be cut by BstN /, where as mutant product will not, enabling
activating mutations of the Ki-ras oncogene to be detected by restriction fragment
length polymorphism (RFLP). To selectively enrich for mutated DNA two rounds of
PCR amplification are used each followed by restriction enzyme digestion with BstN I.
The first PCR contains the 5' modified primer along with an unmodified 3' intronic
primer. After BstNI digestion, in which the 5' portion of any wild type product is
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cleaved, an aliquot of the digest is used as the template for a second PCR. Because the
wild type product has lost its 5' portion it takes no further part in the reaction allowing
the mutant product to be selectively amplified. As an internal control for enzyme fidelity
a second BstNI site can be incorporated in the 3' primer used in the second round of
PCR amplification along with the 5' modified primer. A second BstNI digestion of this
reaction product will remove any wild type product which may have been carried
through from the first reaction allowing easy identification of any mutations by
polyacrylamide gel electrophoresis (PAGE). Mutations detected in the whole gut lavage
fluid samples were confirmed by direct sequencing with a 3' nested primer.
In detail a protocol with modification from Tobi and Kahn (Kahn 1991; Tobi 1994).
was used as follows. The first PCR reaction was performed in a lOOpl volume
containing 20 mM Tris-HCl (pH 8.0), 50 mM KC1, 1.5 mM MgCl2, 10 ng of each
primer and 2.5 units of Taq DNA polymerase for 15 cycles with an annealing of
temperature 55°C. (Primers: sense, with a BstN I restriction site:
5'ACTGAATATAAACTTGTGGTAGTTGGACCT3', antisense, wild type:
5TCAAAGAATGGTCCTGCACC3 .). Using lOpl of the first PCR product a BstNI
enzyme digestion was undertaken with 20 units of enzyme in a final reaction volume
20pl incubated at 60°C for 3 hours. Next a second PCR using lpl of the digestion
product as template was carried out in a 50pl volume. The reaction conditions were
identical to the first PCR except 150 ng of each primer was used and 35 cycles were
performed. (Primers sense: BstNI restriction site, antisense: BstNI restriction site
5 TCAAAGAATGGTCCTGGACC3').
Finally a second BstNI restriction enzyme digestion was undertaken using 20pi of
the second PCR product and 10 units of enzyme in final reaction volume 30pl
incubated at 60°C for 2 hours. The products of digestion were analysed by PAGE
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Figure 2.1 Enriched PCR for Ki-ras codon 12 mutations exploiting a modified





First PCR amplification creates an artificial BstN 1 restriction site at
codon 12 in wild type allele









New BstN 1 cleavage sites are created at the 3' end of the PCR products.
Mutant alleles are selectively enriched small amounts of contaminating wild
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Mutant alleles are cleaved to give 143 bp and 14 bp products. Any residual
contaminating wild type product is cleaved into 119, 24, and 14 bp products.
Digestion products are then resovled by PAGE.
Wild type
| BstN 1 cleavage site
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using a 15% non-denaturing acrylamide gel in the Miniprotean apparatus (Bio-Rad
Laboratories Ltd., Bio-Rad House, Hemel Hempstead, Hertfordshire, UK), lOpl of
PCR product were mixed with 5 pi of loading buffer and all 15 pi were loaded into each
lane. The gels were run at constant voltage (125v) until the Bromophenol blue dye ran
off the end of the gel. The gels were then stained with ethidium bromide (0.5 mg/ml in
500 ml lx TBE) for 20 minutes and destained for 10 minutes in lx TBE buffer and the
products visualised under UV light. Any uncut PCR product was seen on the gels as a
157 bp product. Cleavage ofmutant DNA produced fragments of 143 bp and 14 bp in
length whilst any contaminating wild type DNA would produce fragments of 119 bp, 24
bp and 14 bp in length (figure 2.1).
The mutant band on the 15% polyacrylamide gel was cut out and the DNA extracted
by boiling in DDW for 20 minutes. The extracted DNA (lOpl) was then subjected to a
further Ki-ras PCR amplification using the original 5'-primer and a new nested
3'-primer (5 -CTC TAT TGT TGG ATC ATA TT). The resultant PCR product was
then directly sequenced and compared with a similar PCR product derived from DNA
extracted from the tumour.
p53 codon 248 enriched PCR
The analysis ofp53 codon 248 was undertaken in a similar manner using theMsp I
restriction enzyme. In this assay the primers were not modified to produce artificial
restriction sites, as the wild type sequence at codon 248 produces aMsp I restriction
site (CCGG) and mutation of any of the base pairs in this codon destroys the restriction
site. An initial PCR amplification was undertaken using 5 pi ofDNA from whole gut
2~t~
lavage fluid in a 100 pi reaction containing 10 ng of each primer, 1.5 mM Mg , for 15
cycles, annealing temperature 58°C. (Primers: sense: 5'-TGT GTT ATC TCC TAG
GTT GG, antisense 5-TGG CAA GTG GCT CCT GAC.) A 10 pi aliquot of the first
PCR reaction was digested with 2U ofMsp I in a 20 pi volume at 37°C for 1 hour. A
1 pi aliquot of the digest was then used as a template for a second PCR reaction using
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150 ng of the same primers in a 50 pi reaction for 30 cycles. A second Msp I digest was
performed using 10 pi of the second PCR product. Because the primers were not cut by
the restriction enzyme, to ensure complete enzyme digestion, at each stage positive and
negative controls were included in each assay. This eliminated the possibility of false
positive results by incomplete enzyme digestion. Mutant alleles remained uncut and
appeared as a single 143 bp band, whilst wild type alleles were cut into 85 and 58 bp
products. In tumour samples where mutations were detected, the corresponding whole
gut lavage fluid samples were analysed in a similar manner. All mutations detected were
confirmed by direct sequencing of gel purified products as described previously using a
5' nested primer (5 - TAG GTT GGC TCT GAC TGT ) and the original 3' primer.
Reaction conditions were identical to the those for the second PCR of the enriched
strategy.
2.5 Sequencing ofPCR products
PCR products were sequenced directly using the dideoxy chain termination reaction
as outlined in the manufacturers protocol (Sequenase version II enzyme (Amersham
International, UK )). The sequencing products were radio-labeled by the incorporation
of a35S dATP and run on preheated 40 cm x 30 cm 6% polyacrylamide denaturing gels
with 7M urea. Initially gels were run at 70 watts until the bromphenol blue of the
loading buffer had just run off the end of the gel. The resultant gels were dried and




To allow analysis ofPCR products by autoradiography some PCR products were
end labeled with y33P ATP. First one primer (of the primer pair) was end labeled in a
20 pi reaction containing the primer (5 mM), y33P ATP (0.3 mM) (ICN Oxon England)
and 20 units ofT4 DNA polynucleotide kinase (Gibco BRL, Life Technologies, Paisley,
Scotland) buffering conditions (70 mM Tris, pH 7.6, 0.1M KC1, 10 mM MgCl2 5 mM
Dithiothreitol (DTT), 0.5 mg/ml Bovine Serum Albumin (BSA)). The reaction mixture
was then incubated at 37°C for 1 hour.
In a 50pl reaction lOpl of the appropriate PCR product was labeled using 1.5 pi of
the previously labeled primer; the reverse primer, additional buffer, magnesium,
nucleotides and Taq DNA polymerase were added to achieve standard PCR
concentrations and two cycles of 94°C for 3 minutes, 55°C for 2 minutes and 72°C for
10 minutes undertaken.
2.7 Single strand conformationalpolymorphism.
Both radiolabeled and silver staining techniques were employed to detect
polymorphisms.
For PCR products end labeled with y 33P ATP, 12pl of the PCR product was added
to an equal volume of denaturing buffer (95% Formamide, 20 mM EDTA, 0.05%
Bromophenol Blue and 0.05% Xylene Cyanol) and then resolved on 50% MDE ( FMC
Bioproducts Rockland ME USA) gels containing 10% glycerol. Electrophoresis was
performed at 10 watts and at room temperature overnight. The resulting gels were
dried and autoradiographs taken. Samples were run in duplicate on separate gels.
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For unlabelled products silver staining was performed. The protocol adopted was
identical to that described above except one of the electrophoresis plates was covered
with a bind solution (99.2% absolute ethanol, 0.5% glacial acetic acid and 0.3%
y-methacryloxypropyltrimethoxysilane). The gel on the bind plate was fixed in 10%
ethanol for 10 minutes followed by 1% nitric acid for 10 minutes. It was then rinsed
with DDW for 5 minutes before staining with 12 mM silver nitrate solution for 30
minutes. The gel was then rinsed quickly (10 seconds) with DDW and 100 ml of chilled
developer added (0.3M sodium carbonate decahydrate, 0.019% formaldehyde). As
soon as a precipitate appeared the developer was poured off and 1 litre of fresh
developer added and agitated until bands appeared. The developer was then discarded
and the gel was then fixed with 0.1M citric acid.
2.8 Microsatellite analysis
To determine the replication error (RER) phenotype of the cancers examined in this
thesis five microsatellites were examined by PCR. Two poly A repeats BAT 26 and
BAT 40 (Liu 1996b) and three CA repeat D2S123, D5S346 and D13S60 (Susan
Farrington personal communication) were analysed. (For PCR conditions see
appendix). The PCR products of normal and tumour pairs were end labeled with
y33P ATP and resolved denaturing PAGE (6% polyacrylamide, 7M urea, 0.5x TBE
buffer). The resultant gel were transferred to 3 mm chromatography paper, dried and
autoradiographs taken. Novel alleles were identified by band shifts of the tumour
sample in relation to the paired normal. Gels were run for both forward and reverse end
labeled primers. Tumours were described as RER+ if shifts were seen at two or more
loci.
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2.9 Protein Truncation Test
Some of the analysis ofAPC mutations was undertaken using the protein truncation
test (PTT) as detailed below.
For PCR products to be used as templates for in vitro transcription and translation
the 5' primer must be modified to incorporate four functional regions (Roest 1993).
There is a T7 DNA dependent RNA polymerase transcription initiation sequence, which
is preceded by some spacer nucleotides at the 5' end so that the T7 promoter region is
at least 20 nucleotides long, in order to enhance transcriptional activity. These spacer
nucleotides can incorporate a restriction site (e.g. Bam HI) to aid cloning amplification.
The T7 promoter is linked to a ribosome binding sequence immediately followed by an
ATG translation initiation codon coupled, in an in frame manner, to the relevant gene
specific primer . The antisense primer was not modified. PCR amplification using these
modified primers was undertaken in the manner previously described. Cycling
conditions were different because of the long length of the 5' primer and the PCR
product. These were typically a denaturation time of 60 s., an annealing time of 60 s.,
and an extension time of 90 s.
The PCR products were then used as a template for a single tube in vitro
transcription / translation reaction (TNT Quick ® , Promega Biotech, Southampton,
UK). Reactions were performed as described in the manufacturers protocol using 5pi of
PCR product as a template. The protein products were radiolabeled by the
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incorporation ofa S Methionine (ICN Oxon England). To ensure successful
translation a leuciferase control reaction was performed in each reaction which
produced a 61 kDa protein product. Protein analysis was performed by SDS-PAGE as
described in the manufacturers protocol. In each case the samples were run on 10%
12.5% and 15% gels. The gels were dried on 3 mm chromatography paper and
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autoradiographs produced. Truncated proteins were identified as abnormally fast
migrating bands on the autoradiogram.
2.10 Telomerase PCR ELISA
Telomerase activity in whole gut lavage fluid samples was assessed using a PCR
ELISA technique (commercially available from Boehringer Mannheim) based on the
Telomeric repeat amplification protocol (TRAP) (Kim 1994). All experiments were
conducted as recommended by the manufacturer's protocol with the following
modifications. The protein concentration of the cell lysates and whole gut lavage fluid
samples were calculated as described below (section 2.11) and divided into aliquots
containing 50 mg of total protein, snap frozen in liquid nitrogen and stored at -70°C.
The TRAP reaction was performed using 25 or 50 mg of lysate or whole gut lavage
fluid protein in a 50pl reaction. The optimum cycling conditions were modified until a
characteristic ladder pattern consisting of multiple PCR products increasing by 6 bp
increments was produced when resolved on MDE gels as for microsatellite analysis.
These were an initial incubation at 27°C for 30 minutes then telomerase inactivation at
94°C for 5 minutes followed by PCR amplification of 35 cycles, 94°C denaturation for
45 seconds, 50°C annealing for 45 seconds, 72°C elongation for 90 seconds, with one
final elongation of 10 minutes at 72°C. Cells known to have telomerase activity (either
Kidney 293 or Colon cancer HT29) were used as positive controls with the negative
control being heat inactivated cells (15 minutes at 94°C). PCR products were
transferred to streptavidin coated microtitre plates and the ELISA performed using kit
reagents according to the manufacturers protocol. Microtitre plates were analysed on
an MRX Microplate reader using MRX Revelation software (version 3.02).
Absorbency was measured at 450 nm with a reference wavelength of 630 nm. For
successful interpretation of the ELISA absorption readings of greater than 1.0 A450nm -
71
A630nm for the positive control and less than 0.2 A45onm - A^onm for the negative
control were required for each experiment.
2.11 Protein concentration assay
Protein concentrations of cell lysates and whole gut lavage fluid were measured
using a Bicinhoninic Acid (BCA) assay (Pierce Chemical Company). The manufacturers
protocol was followed and ELISA plates read at 405 nm. Using the absorption data a
standard curve for known protein concentrations was produced and the equation of the
line calculated using a computer spread sheet (Microsoft Excel ® Version 6.0). This
equation was then used to calculate protein concentrations for unknown samples from
their absorption readings.
2.12 Nuclear Ploidy
Nuclear DNA ploidy was assessed by Mr. Robert Morris (ChiefMLSO) using
published methods (Vindelov 1983). Briefly for fresh tissue small tissue fragments were
suspended in a citrate buffer and then treated with trypsin for 10 minutes. A trypsin
inhibitor was then added before staining the cells with propidium iodide. For paraffin
embedded tissue 50pm sections were cut, placed on a glass slide and rehydrated. The
rehydrated sections were incubated with 1 ml of pepsin solution (0.5% pepsin, 0.9%
saline pH 1.5) at 37°C for 60 minutes. Samples were then washed with Phosphate
buffered solution (PBS). The resulting solution was filtered through a 70pm sieve and
the supernatant removed after centrifiigation. Nuclei were stained with propidium
iodide.
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Flow cytometry analysis was then undertaken using EPICS (Coulter Ltd,
Beaconsfield, Bucks, UK). Solutions were diluted to 106 cells per ml and 5000 nuclei
were counted for each analysis.
2.13 Loss ofHeterozygosity analysis ofAPC
Polymorphic sequences in the 3' untranslated region ofAPC and APC exon 11 were
analysed by restriction fragment length polymorphism (Curtis 1994). PCR reactions
were performed in 100 pi volumes. Each reaction contained 200 ng of genomic DNA
and 50 pmol of the appropriate primer (Appendix 1). Cycling conditions consisted of
an initial denaturation step of a 5 minutes at 94 °C. Followed by 30 cycles of
denaturation for 30 seconds at 94 °C, 30 seconds at a specific annealing temperature
and 60 seconds at 72 °C to allow extension, with a final extension step of nine minutes
at 72 °C. PCR products were analysed by gel electrophoresis following restriction
enzymes digestion as required.
For restriction enzymes digestion, PCR reaction products were ethanol precipitated,
resuspended, and the entire sample incubated overnight with five units of the
appropriate enzyme, according to the manufacturer's recommendations. The 3'
untranslated APC region contained an Ssp I polymorphism, cleavage product sizes
were: allele 1 270 bp and allele 2 135 bp, this reaction also contained a constant band
at 580 bp which plays no part in the determination ofLOH. Products were resolved on
3% agarose gels. APC exon 11 contains a Rsa I polymorphism with product sizes of
132 bp for allele 1 and 87/45 bp for allele 2. These products were resolved on 12%
polyacrylamide gels. Gels were stained for 30 minutes in 0.5 mg/ml ethidium bromide
and DNA fragments visualised by UV illumination. Allele loss or retention was
evaluated by eye.
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2.14 Study Popu lation
Whole gut lavage samples were collected pre-operatively from 40 patients with
confirmed colorectal cancer and these patients form the basis of the study population.
For each patient normal and tumour DNA were obtained for comparison from
representative sections from the paraffin sections of the surgically resected specimen.
The median age of the study population was 71 years (range 39 - 90) with a male :
female ratio of 24 : 16. There were 7 Dukes A carcinomas, 14 Dukes B, 17 Dukes C
and 2 metastatic lesions; 7 right-sided tumours, 16 left and 17 rectal (See table in
Appendix 2). In addition whole gut lavage fluid samples were obtained from 15 patients
undergoing bowel preparation for diagnostic colonoscopy (for alteration in bowel habit)
which was ultimately normal.
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3. Cytology of whole gut lavage fluid
In order to optimize subsequent sample analysis potential methods of cell isolation
from whole gut lavage fluid were undertaken. Expected benefits of cell isolation were
firstly a reduction in potential PCR contamination when using DNA obtained from
whole gut lavage fluid samples. Secondly, a relative concentration ofmutant DNA with
respect to the vast excess of normal DNA from inflammatory cells in whole gut lavage
fluid samples if inflammatory cells could be separated from epithelial cells. Thirdly the
concentration of any mutant cells may also be allow the use of immunohistochemical
techniques to detect p53 stabilization by flow cytometry.
Methods
Discontinuous density elution gradients familiar to the GI Laboratories and
continuous density gradients (detailed in section 2.2) were employed. For each sample
visible cell layers were harvested cell counts were performed and cytospin slides were
made using aliquots of 50 and lOOpl from each sample. These slides were then stained
with haematoxylin and eosin prior to microscopic examination.
Whole gut lavage fluid samples from 8 patients were processed on a discontinuous
density gradient and 10 were processed using a continuous density gradient. There
were 8 samples taken from cancer patients and 10 from normal controls. These control
patients were patients whom had a diagnostic colonoscopy for positive family history
which ultimately was normal. In a further 5 whole gut lavage fluid samples from cancer
patients only cytospin slides were made.
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Results
The mean cell counts per ml for each sample are shown for cancer samples and
normal samples in figure 3.1. There was no difference in the mean cell counts per ml for
cancer patients when compared to normal subjects (Mann-Whitney U Statistic = 55.0,
p=0.453; Students t-test p=0.313).
A qualitative assessment of the purification of each sample was made by examining
the H & E slides with a Consultant Histopathologist specializing in cytometry. Bacteria
were ubiquitous in all the samples examined as was particulate debris. Despite the
attempted cell separation all slides examined had severe and persistent bacterial and
debris contamination. Where cells were identified white blood cells particularly
neutrophils and macrophages were most frequently identified followed by squamous
epithelial cells, red blood cells and occasionally lymphocytes. Cells representing colonic
epithelium or neoplastic cells were seldom identified. Of the 52 slides examined from 13
cancer patients no samples showed overtly neoplastic cells and only 4 slides (in 4
different patients) showed cells that were regarded as suspicious of neoplasia. It was
clear from the above analysis of these initial samples that purification did not confer any
potential benefit for subsequent DNA extraction and later samples were not processed
in this way.
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Whole gut lavage from cancer or normal subject
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Discussion
Cell count alone did not discriminate between cancer and normal samples. Since
many neoplasms frequently bleed and may be sources of substantial numbers of
exfoliated cells they might have been expected to significantly increase cell counts in
whole gut lavage fluid. Increased cell counts in whole gut lavage fluid are noted in
patients with active inflammatory bowel disease this is principally due to inflammatory
cells (Handy 1995). The mean cell counts for my samples were an order of magnitude
greater than that described in previous work (Handy 1995). However cell recovery
from stool samples varies over a wide range (Gordon 1991) and the difference between
my results and others could represent inter sample variation or a difference in early
processing of the samples. The particulate debris widely noted in the samples may also
artificially elevate cell counts. Colonic epithelial cells and neoplastic cells were a rare
finding which is in agreement with other studies (Gordon 1991; Handy 1995).
Inflammatory cells and squamous cell were frequent findings. This is probably because
inflammatory cells are designed to migrate in to different environments to confer host
immunity and as such are likely to be robust and capable of surviving in the colonic
lumen. Conversely colonic epithelial cells are only sloughed into the colonic lumen
when in a state of degradation, undergoing apoptosis, and so would not be expected to
last long in the colonic lumen. Squamous cell represent unavoidable contamination of
the sample from the anal margin, or possibly from the nasopharynx and oesophagus.
Purifying the whole gut lavage fluid samples by density gradients proved
unsatisfactory. It had been hoped that the use of these density gradients would help
separate cells in the whole gut lavage fluid sample from the bacteria and particulate
debris. Two main problems were encountered. Firstly, the passage of particulate debris
through the density gradient destroyed it. For the discontinuous gradients most of the
cells remained on the top of the gradient with only small proportion passing through the
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gradient to the second layer. There was also no separation of the cells into different
colonies at these two layers. These findings were also noted in previous work (Handy
1995). For the continuous gradients no discrete layer of cells suitable for extraction was
formed. Subjectively, particulate debris could be seen throughout the continuous
gradient contaminating it at every level. Microscopically the same problem was noted
with bacteria. Secondly, the amount ofbacteria and particulate debris was far in excess
of the cellular material. Although many bacteria were removed by the gradients, they
still far out numbered any cells. Preparations using spin gradients removed a lot of the
faecal debris but also removed a substantial proportion of the cellular material. Removal
of this contamination lead to major loss of the cellular material available for analysis. In
all samples persisting debris contamination meant that flow cytometry analysis ofwhole
gut lavage fluid for p53 stabilization would not be possible.
These cytological investigations permit the following conclusions. Firstly cells with
recognizable morphological features are recovered in large numbers from the whole gut
lavage. Presumably these samples will contain many cells with pyknotic nuclei and other
non-viable cell degradation products. It is therefore reasonable to expect that genomic
DNA to be available for PCR amplification albeit, heavily admixed with bacterial DNA.
Secondly there is no significant alteration in cell number recovered from cancer patients
and those with macroscopically normal colons. The differences in recovery ofmutant
versus normal DNA is unlikely to reflect trivial reasons such as greater availability of
cells in cancer patients. Finally, epithelial cells are always in the great minority and well
preserved tumour cells were never seen. This confirms that this method is limited for
cancer diagnostic purposes by conventional cytology. The absence of colonic epithelial
cells and the infrequent finding of suspicious or malignant cells tends to favour a DNA
based approach to colon cancer screening. Small fragments ofDNA from apoptotic
colonocytes or neoplastic cells may persist in whole gut lavage fluid where cells can no
79
longer be identified. The question thus remains whether the enhanced sensitivity
afforded by PCR has the capacity to generate diagnostic information.
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4. PCR amplification of DNA extracted from whole gut
lavage fluid
In order to identify the best method ofDNA extraction several methods were
evaluated. The end points for this evaluation were the total DNA yield and successful
PCR amplification of the extracted DNA. Much of the previous work on PCR
amplification ofDNA obtained from stool has been hampered by inhibition of the PCR
(Sidransky 1992; Tobi 1994; Hasegawa 1995; Smith-Ravin 1995; Nollau 1996; Villa
1996). This has been attributed to faecal contaminants in the PCR which can be
partially removed by the use of spin column purification (Smith-Ravin 1995). For this
reason, spin column purification was included as a final step in each of the DNA
extraction protocols. In addition, it has been estimated that human DNA accounts for
only 10% of the total DNA extracted from stool (Hasegawa 1995). It would be
reasonable to assume this proportion is similar in DNA extracted from whole gut lavage
fluid. PCR amplification of the mitochondrial sub-units cytochrome b and cytochrome
oxidase has been used to confirm the presence of human DNA in DNA extracted from
stool. These mitochondrial DNA fragments are present in high copy number in
eukaryotic cells. Their PCR products are 300 bp in size for cytochrome b and 1.4 kb for
cytochrome oxidase (Smith-Ravin 1995). The PCR amplification of these mitochondrial
subunits was therefore used to determine the best DNA extraction method and confirm
the presence of human DNA in the DNA extracted from whole gut lavage fluid.
Because cytochrome subunits are present in high copy numbers in each cell it is
expected that they will amplify easily. The amplification of single copy genes might not




One patient undergoing an ultimately normal diagnostic colonoscopy for altered
bowel habit was able to provide in excess of 500 ml ofwhole gut lavage fluid. This was
divided into 25 ml aliquots and one aliquot was used for each of three previously
published methods ofDNA extraction (Tobi 1994; Smith-Ravin 1995; Eguchi 1996).
Various elements of each of the individual methods were also combined and evaluated
using the same whole gut lavage fluid sample as detailed above. Final end points
measured were the total DNA yield as measured by spectroscopy (section 2.3). PCR
amplification of cytochromes b and oxidase was undertaken using 50 ng ofwhole gut
lavage fluid DNA (for reaction conditions see appendix 1). PCR products were
resolved on agarose gels, stained with ethidium bromide and the intensity of the
product bands compared subjectively by eye. The DNA extraction method that
ultimately gave the most intensely stained PCR product was adopted as the preferred
method ofDNA extraction. This proved to be a method based on the extraction method
published by Smith-Ravin et al. (Smith-Ravin 1995) and modified as described in
section 2.3.
There was some concern about the accuracy of the DNA concentration estimation
by spectroscopy. The DNA concentrations were therefore re-measured at a later date
by UV fluorescence estimation. Even here technical problems were encountered. In
samples where the DNA concentration was less than 10 ng/pl the image on the BioRad
viewer was of insufficient quality to allow the software to calculate a DNA
concentration. Visual estimation on a standard UV lightbox had to be undertaken for
these samples. Some 10 samples had such a low intensity fluorescence image that even
estimation by eye was impossible. These samples were given a concentration and yield
value of zero.
82
Using the optimal method DNA was extracted from 100 ml of the 40 whole gut
lavage fluid samples forming the study population. The DNA yield for each sample was
initially estimated using spectroscopy measurements this was later repeated using UV
fluorescence estimates. Each of the 40 samples ofwhole gut lavage fluid DNA was
subjected to analysis of cytochromes b and oxidase using published methods (Smith-
Ravin 1995). In addition the single copy gene Ki-ras was amplified for each sample.
(Reaction conditions are detailed on appendix 1.)
Results
The first attempts to extract the DNA from whole gut lavage fluid resulted in brown
pigmented solution even after passage through spin columns. Electrophoresis of a 5pi
aliquot of this solution on to ethidium bromide stained gels did however produce a
smeared band confirming the presence ofDNA. Further DNA extractions on the
control sample were evaluated to try and remove this pigmentation. Repeated phenol /
chloroform extractions eventually resulted in unacceptable losses ofDNA with each
successive extraction producing only a minor reduction in the pigmentation. Subjective
analysis ofDNA smears on agarose gels suggested the optimal extraction method
proved to be two phenol / chloroform extractions followed by passage through a
commercial spin column. This still allowed amplification of the cytochrome b
mitochondrial subunit (appendix 1) using 50 ng of the DNA obtained from the whole
gut lavage fluid. This method was therefore employed to extract DNA from the whole
gut lavage fluid samples used to make the study population.
For the 40 samples which made up the study population the mean total amount of
DNA per 100 ml sample (measured by spectroscopy) was 2.35 pg (SD 3.75 pg)
however the median value was 1 pg (interquartile range 0.005 to 3.15pg). However the
majority of the samples lie between 0 and 7 ng/pl with 2 samples producing high yields
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skewing the mean figure. When the samples were re-examined using UV fluorescence
measurements the mean total amount ofDNA was 2.58 pg (SD 4.2 pg) with a median
value of 1.25 pg (interquartile range 0.28 to 3.53 pg). (Figure 4.1)
Cytochrome b and oxidase analysis confirmed the presence of non-bacterial DNA in
37/40 (93%) of whole gut lavage fluid samples. Despite the pigmentation of some
samples Cytochrome b was amplified in 37/40 samples however cytochrome oxidase
with a larger amplification product could only be amplified in 16/40 (40%) ofwhole gut
lavage fluid DNA samples. There were no cases where cytochrome oxidase could be
amplified and cytochrome b could not. (Appendix 2)
The analysis of the single copy gene Ki-ras was less successful with only 19/37
(51%) of samples from colorectal cancer patients amplifying successfully. The mean
total DNA (using spectroscopy measurements) for these 19 samples was 3.42 mg (SD
4.92 mg). There was no difference in the total DNA of this group when compared to
those in which cytochrome b was amplified (SE diffi = 1.626, p=0.12). The mean total
DNA for these same samples when measured using UV fluorescence was 2.66 pg (SD
2.52 pg). The scatter diagram of those samples which did successfully PCR amplify Ki-
ras and those that did not would suggest a significant difference in the total DNA
yields. However the difference in the median values for DNA yield are not statistically
different. The median DNA yield for samples which amplified Ki-ras was 2.00 pg
(interquartile range 0.50 - 4.26) compared with a median value of 0.71 pg (interquartile
range 0.00 - 2.46) Mann-Whitney U statistic = 146 (p = 0.146).
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Figure 4.1 Scatter diagram comparing the DNA yield (from 100 ml ofwhole
gut lavage fluid) of samples that successfully amplified Ki-ras to those that did
not.
Sample
♦ Successful Ki-ras PCR amplification
□Unsuccessful Ki-ras PCR amplification
n fig sd
Mean DNA yield for samples that successfully amplified Ki-ras 19 2.66 2.52
Mean DNA yield for samples that unsuccessfully amplified Ki-ras 21 2.52 5.28
Standard error ofdifference ofmeans 0.82 (Not significant p >0.5)
Median DNA yield for samples that successfully amplified Ki-ras
Median DNA yield for samples that unsuccessfully amplified Ki-ras
pg interquartile range
2.00 0.50 - 4.26
0.71 0.00 - 2.46
Mann - Whitney U test Statistic = 146, p = 0.1473
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Discussion
DNA extraction from whole gut lavage fluid proved troublesome. Few of the papers
looking at mutational analysis in stool samples discuss the amount or quality ofDNA
obtained from stool. Smith-Ravin and colleagues showed that DNA samples extracted
by simple phenol / chloroform extraction failed to amplify by PCR even when the
samples were spiked with high quality DNA concluding that some PCR inhibitors
persist even after phenol / chloroform extraction. They also demonstrated that these
inhibitors could be removed to some extent by using spin columns designed for
purification of plasmid DNA (Smith-Ravin 1995). Using spin column preparation the
total DNA yield varied between 0 and 7 pg (with two exceptions). Villa el al. obtained
a mean of 7.3 pg ofDNA from 100 mg stool samples from patients with colorectal
cancer (Villa 1996). (No other study documents the DNA yield.) This yield is double
the mean of this study and some seven times greater than the median value. This
difference may represent differences in sample type or more likely differences in DNA
extraction. Villa employing a glass milk extraction stage rather than spin column
preparation. Glass milk purification has been shown to be less effective than spin
column purification (Smith-Ravin 1995).
The persisting pigmentation in some samples would suggest persisting contamination
that hampers DNA concentration estimation and possibly PCR amplification. The
problems in estimating the DNA concentration were overcome using UV fluorescence
measurements but in several cases the ultimate DNA yield was so low that it was not
possible to accurately estimate the DNA concentration even using UV fluorescence
techniques. It is also possible that the pigmentation lead to some quenching of the UV
fluorescence leading to an under-estimation of the DNA yield. Previous work in the
colorectal cancer laboratories in Edinburgh has shown that DNA extraction from lung
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cancers can result in a persistent black colouration following phenol / chloroform
extraction yet these samples still amplified by PCR (L. Curtis personal communication).
PCR amplification of cytochrome b was possible in 93% of the study population.
This PCR product is 300 bp in length. Amplification of the cytochrome oxidase subunit
with a product size of 1.4 kb was less successful. Microscopy ofwhole gut lavage fluid
samples demonstrated rather degenerate cells many ofwhich are presumably
undergoing apoptosis which is known to degrade DNA into fragments of- 200 bp
(Wyllie 1980). This along with any DNase secreted by bacteria and digestive juices
would lead to degraded DNA when extracted as illustrated by smears on
electrophoresis. Any free DNA in the whole gut lavage fluid will be in a similar state of
degradation. DNA smears do show some high molecular weight DNA this most
certainly represents bacterial DNA. In contrast it has been noted that low molecular
weight DNA fragments can persist in the aqueous phase ofDNA solutions even after
precipitation and pelleting the DNA in a centrifuge at high g (Wyllie 1980). Hence it is
possible that some of the tumour DNA useful for analysis may be lost in the discarded
supernatant.
Amplification of the Ki-ras gene fragment (143 bp) was successful in only 51%
cases available for analysis. There is a tendency although not statistically significant for
whole gut lavage fluid samples that do amplify Ki-ras to yield more DNA. This has also
been noted in stool samples (Cruickshank 1996). The difficulty in amplifying single
copy genes probably reflects the culmination of all the above problems namely reduced
DNA yield due to repeated purification, persisting PCR contaminants, and degraded
DNA.
In this section I have demonstrated that DNA can be obtained from whole gut lavage
fluid but in a rather degraded and impure form. This would suggest that for successful
mutational analysis by PCR techniques product sizes should be kept small and highly
sensitive detection methods are required.
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5 Development of Transforming Growth Factor Beta
Receptor II assay
The extensive interrogation ofmany microsatellites to determine RER status is
labour intensive and not ideally suited to the screening situation. The close correlation
between TGFfiRIImutations and the RER+ phenotype (Parsons 1995b) would suggest
RER status can be evaluated using a single test. Other work would suggest similar
information can be obtained by interrogating the BAT 26A locus (Hoang 1997). In
order to assess whether such a high correlation was applicable to the Scottish
population and to develop a robust assay that could be applied to whole gut lavage fluid
DNA a separate series of 18 archived cancers with previously determined RER status
was initially assessed for TGFfi RIImutations.
The RER phenotype for each control patient was determined by examining
microsatellites as published (Parsons 1995b; Liu 1996b). DNA from paraffin sections of
the tumour and normal colonic mucosa were amplified by PCR and the resulting
products end labeled with y33P ATP. The labeled products were analysed in
normal/tumour pairs by electrophoresis through denaturing polyacrylamide gels (6%
acrylamide, 7M urea run at 50°C for one hour). Novel alleles were detected as shifts in
the electrophoresis band pattern between normal and tumour. An RER+ phenotype was
assigned if shifts were noted in at least two microsatellites. The microsatellites studied
were BAT26A a 26 polyadenine repeat in an intron of the MSH2 gene on chromosome
2, BAT40A a 40 polyadenine repeat in the 3 Beta hydroxylase gene (Parsons 1995b),
and the CA repeats D2S123, D5S346, and D13S60 (S. Farrington personal
communication), as these were known to exhibit microsatellite instability in 98% of
RER+ tumours (Liu 1996b, Parsons 1995b). The RER status was then compared to the
presence or absence of TGFfiRII mutations (vide infra) in the control DNA. Finally
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TGFfiRIImutations were sought in whole gut lavage fluid by the same method and
compared to that detected in the control tumour DNA.
The genetic defect responsible for the increased cancer susceptibility for patients
with HNPCC has been attributed to germ-line mutations in the family of genes
encoding proteins responsible for mismatch repair ofDNA (Kinzler 1996). To date
mutations in four genes in this family have been identified (MSH2, MLH1, PMS1 and
PMS2) (Cunningham 1996). Mutations in any one of these genes confer a genomic
instability characterised by microsatellite instability or replication error (RER+). The
genes themselves are not oncogenes or tumour suppresser genes. They are thought,
through the inherent genomic instability, to predispose to mutations in other oncogenes
or tumour suppresser genes (Kinzler 1996). The characteristic lesion in RER+ tumours
are short insertions or deletions in repeated sequences e.g. Poly A or CA repeat
sequences (Aaltonen 1994). The majority of such sequences are either intronic or
intragenic and as such mutations in these regions are unlikely to produce neoplastic
mutations.
Transforming growth factor beta 1 (TGFB) is an important inhibitory growth
regulatory protein in embryogenesis and in epithelial cells throughout life. It has been
shown that TGFB acts through three membrane receptors and that mutations in TGFB
RII block cell signaling of TGFB and confer neoplastic properties. The RII gene
contains a 10 bp poly A (Ai0) sequence which may be susceptible to mutation in MMR
deficient individuals. Indeed it has been shown that this gene contains a mutation in this
region in 90% ofRER+ tumours and cell lines (Parsons 1995b). Thus it would make a
suitable target for genetic screening ofHNPCC families.
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Figure 5.1 Microsatellite instability analysis at loci D2S123, BAT26 and
BAT 40
NT NT NT
D2S123 BAT 26 BAT 40
Three representative gel photos to show microsatellite instability
For each sample normal and tumour DNA was amplified and the PCR products
were end labelled with y33P ATP. These radiolabeled products were resolved on
polyacrylamide gels. The gels were dried and contact autoradiographs produced
by overnight exposure in cassettes with intensifying screens.
Examples here show normal and tumour pairs for the CA repeat D2S123, and the
polyA sites BAT 26 and BAT 40. In each case the tumour sample shows
microsatellite instability indicated by presence of novel alleles (*).
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Development ofassay
The work by Parsons et al. identifying TGFfiRIImutations in RER+ cancers and
cell lines (Parsons 1995b) was performed on cDNA. Their analysis used a 73 bp PCR
fragment that spanned the A10 section. The products were resolved on denaturing
polyacrylamide gels allowing resolution of 1 - 2 bp shifts. Using their published primers
and reaction conditions and despite rigorous optimisation I was unable to obtain
sufficiently clean reaction products to perform a similar analysis on genomic DNA. At
this time the genomic sequence for TGFfi RII was not in the public domain. Attempts at
redesigning the primers were unsuccessful because of an intervening intron whose
location was at that time unknown. Publication of the genomic sequence of TGFfi RII
localized the A10 segment to exon 3 and the use of their published intronic primers
enabled successful amplification ofDNA from all sources. Mutational analysis was then
performed by SSCP (Lu 1996).
To assess the assay firstly cell lines with known mutations in the TGFfi RII gene
were analysed. The cell lines HCT 116 and LoVo are known to harbour deletion /
insertion mutations in the A10 repeat (Parsons 1995b). Radiolabeled SSCP on MDE
gels (as outlined in the materials and methods section) confirmed a suitable assay, clear
mobility shifts were seen when compared to a normal control SW 480. Next archive
DNA from 18 cancers known to exhibit MIN at one or more loci was analysed in a
similar manner.
Results
These are summarised in Table 5.1. Of the 18 samples 12 exhibited an RER+
phenotype, 6 showed MIN at only one locus. Of the 12 RER+ cancers 7 (58%) had a
mutation in TGFfiRII as did 1/6 (16.7%) cancers withMIN at one locus.
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Figure 5.2 SSCP analysis of TGFJi RII mutations in RER+ cancers with
normal tissue controls.
NT NT NT
Using PCR techniques, exon 3 of the TGFfi RII gene was amplified for each
sample in normal and tumour pairs. The PCR products were end labelled with
y33P ATP and resolved on non denaturing polyacrylamide gels. The gels were
dried and contact autoradiographs produced by overnight exposure in cassettes
with intensifying screens.
The above image shows representative samples in normal tumour pairs. A
TGF\3 RII mutation can be clearly seen in lane 2 (*).
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Table 5.1 Transforming growth factor beta receptor II mutations in 18 cancers
known to exhibit microsatellite instability
Sample MIN (no. of Loci) RER Phenotype TGFBRII exon 3 SSCP
1 4 Pos Shift
2 2 Pos Shift
3 4 Pos Shift
4 2 Pos No shift
5 4 Pos Shift
6 3 Pos Shift
7 2 Pos No Shift
8 2 Pos No Shift
9 2 Pos No Shift
10 4 Pos No Shift
11 1 Neg No Shift
12 1 Neg No Shift
13 1 Neg Shift
14 1 Neg No shift
15 1 Neg No shift
16 1 Neg No shift
17 4 Pos Shift
18 4 Pos Shift
MIN Microsatellite instability.
(Loci examined BAT 26, BAT40, D2S123, D5S346, D13,S60)
RER Replication error
12 of 18 samples (67%) exhibited an RER+ phenotype
7 of 12 samples (58%) with an RER+ phenotype had a TGF Beta Receptor II
mutation in exon 3 when analysed by SSCP
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Discussion
This small series has shown TGFfi RII mutations in 58% ofRER+ cancers. This is
less than the 90% described by Parsons et al. (Parsons 1995b). This may reflect the use
of SSCP for mutation detection. SSCP is known to be less sensitive that other methods
ofmutation detection. One other series that employed SSCP identified TGFfiRII
mutations in 85% ofRER+ or HNPCC cancers (Akiyama 1997). Whereas another
study that used direct sequencing identified TGFfi RII mutations in 58% ofRER+
cancers (Togo 1996). The study by Parsons analysed many cell lines rather than just
DNA from cancers and the high rate of TGFfiRII mutations may reflect the fact that
cell lines can undergo additional mutations in the process of immortalisation.
Parsons examined cDNA looking for resultant 1 or 2 bp shifts by electrophoresis on
large polyacrylamide gels. However Taq polymerase slippage at the Ai0 site means that
artificial mutations can easily be generated due to poor fidelity of the polymerase
enzyme. The method used by Parsons to control for this still relied on the subjective
interpretation of several bands for each sample which may account for the higher
estimates of TGFfi RII mutations (Parsons 1995b). The mutation pattern produced by
SSCP is clearer and open to less subjective interpretation.
In a study of sporadic colorectal cancers Akiyama et al. demonstrated a RER +
phenotype in 22 /69 (32%) carcinomas Yet only 7/69 (10%) showed a 1 or 2 bp
deletion mutation at the Ai0 site (Akiyama 1996). The 18 cancers in my study were
chosen on the basis ofMIN and RER + phenotype but were chosen from a large
archive of sporadic cancers. This study population probably comprises of a mixture of
sporadic RER + cancers and true HNPCC cancers. This would account for the low rate
of TGFfiRII mutations when compared to Parsons series but high rate when compared
to Akiyama.
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It is interesting to note in the main study population of 40 patients, from whom
whole gut lavage fluid was obtained, 2 of the cancers showed a RER+ phenotype and
both of these cancers had a TGFJ3R1I mutation (Appendix 2).
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6 Mutational analysis ofwhole gut lavage fluid DNA
Point mutations in Ki-ras codons 12 and 13 occur in 40 - 50% of cases of colorectal
cancer (Bos 1987); p53 mutations occur in 50 -75% of colorectal cancers with half of
the transition mutations occurring at codons 175, 248 and 273 (Nigro 1989; Hollstein
1991). Therefore, examination of a range ofmutation sites associated with colorectal
cancer will be required to achieve an acceptable level of sensitivity for genetically based
diagnostic tests (Sidransky 1994). Some 80% of patients with colorectal cancer have
APC mutations that occur throughout its coding region with no particular hot spot, but
mutational clustering is noted in exon 15 (Miyoshi 1992). For the small subset of
cancers with a replication error phenotype (RER+), 90% are reported to have a
frameshift mutation in a 10 base pair polyadenine sequence in exon 3 of TGFJ3 RII
(Parsons 1995b; Lu 1996). Although a few cancers will contain mutations in more than
one gene, the cumulative effect of systematic analysis at these sites in addition to the
point mutations at Ki -ras codon 12 andp53 codon 248 would be expected to identify
mutations in virtually all colorectal cancer and hence might provide a comprehensive
screening method, if applied to stool or colonic washings. No systematic study of this
array of genes in stool or colonic washings has been reported although there have been
opportunistic reports in which one or two sites were interrogated.
The studies examining Ki-ras mutation detection in stool (Sidransky 1992; Tobi
1994; Hasegawa 1995; Smith-Ravin 1995; Cruickshank 1996; Nollau 1996; Villa 1996)
have employed a variety of detection methods with varying success. They all however
make use of techniques which selectively enrich for a particular point mutation. A
similar technique to examinep53 codon 175 mutations has been used with limited
success (Carpenter 1995).
For the analysis of point mutations I employed the technique of enriched PCR which
has been shown to be one of the most sensitive techniques capable of detecting 1
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mutant allele in 10 normal alleles (Kahn 1991). In addition this technique avoids the
use of radioactive isotopes making it an attractive method for a potential screening test.
The nature of the mutations in APC and TGFfiRII means that there are no suitable
point mutations to allow interrogation by an enriched PCR technique and SSCP was
employed to examine these genes. SSCP has also been used to examine exons 5-9 of
p53 in the stool of cancer patients (Eguchi 1996).
Methods
As a proof of principle I initially interrogated DNA samples from the study
population for mutations at codon 12 of the Ki-ras gene,p53 codon 248, exon 3 of
TGFfi RII and in the MCR ofAPC (as described in the materials and methods section).
Ki-ras mutations in whole gut lavage fluid DNA were also sought in 15 control
patients. Examination ofKi-ras and p53 was performed as described in the materials
and methods section.
The majority ofAPC mutations produce premature stop codons and as such the
protein truncation test (PTT) is an ideal technique for their detection. For a successful
assay a protein product of at least 300 amino acids (i.e. a PCR template of at least 1
Kb) is required to produce a product containing sufficient radiolabeled methionine for
detection by autoradiography. Previous analysis of the DNA from whole gut lavage
fluid using mitochondrial fragments had shown that products of approximately 1 Kb
cannot be readily amplified. It was therefore elected not to analyze for APC mutations
in whole gut lavage fluid using the PTT. The MCR region of the APC gene was
therefore divided into 4 overlapping sections (Cooper 1996). These sections were then
amplified by PCR and the resulting products analysed for mutations by SSCP on MDE
gels. A technique with which this lab is fully conversant.
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Results
These are summarised in Table 6.1. There were 26 mutations in 18/40 primary
tumours (45%); 7 Ki-ras mutations, 2 p53 mutations, 2 TGFfi RIImutations and 15
APC mutations. In the DNA extracted from whole gut lavage fluid 2/7 Ki-ras; 2/2 p53
mutations; 0/2 TGFfi RIImutations and 0/15 APC mutations were detected.
Direct sequencing of the PCR products from control DNA from the resected
tumours detected 7 Ki-ras codon 12 mutations (Table 6.1). It was possible to amplify
the Ki-ras gene from DNA extracted from the whole gut lavage fluid in 19/40 samples.
Two of the known Ki-ras mutations were detected by enriched PCR of the DNA
extracted from whole gut lavage fluid (figure 6.1). In 5 cases the known mutation was
not detected. In one sample whole gut lavage fluid PCR amplification was achieved
but a wild type electrophoresis pattern was produced and in the remaining 4 no
amplification was achieved. In addition one whole gut lavage fluid sample showed a
mutation which was not detected in the tumour DNA by direct sequencing despite
repeated investigation. No mutations were detected in the 15 control whole gut lavage
fluid samples. Of these 15 samples 9 amplified successfully and produced negative
assays and 6 would not PCR amplify.
Restriction enzyme digestion of tumour DNA identified 2 p53 codon 248 mutations
and both of these were detected in the corresponding whole gut lavage fluid DNA
(Figure 6.2).
The SSCP analysis ofAPC on control samples was shown to be sufficiently
sensitive to identify 1 mutant allele in 50 wild type. Similar analysis of TGFfi RII
showed a sensitivity of 1 in 20.
There were 2 TGFfi RIImutations detected by SSCP in the paired normal and
tumour control samples. Neither of these mutations were detected by SSCP analysis of
the corresponding whole gut lavage fluid DNA. In one case no PCR product was
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Figure 6.1 Enriched PCR for Ki-ras codon 12 on DNA obtained from whole
gut lavage fluid from patients with known colorectal cancer
1 >
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Enriched PCR products for Ki-ras codon 12. PCR products were resolved on
the 12% polyacrylamide gel then stained with ethidium bromide and viewed
under ultraviolet light. The image has been captured on the BioRad gel
documentation system and inverted to produce a negative image. No other
computer enhancement has been used.
M: one kilobase marker
1: uncut control PCR product
2: positive control cut with Bst Nl. In the second PCR reaction the 3' primer
contains a modified BstNl restriction site and hence mutant PCR products
were cleaved into two fragments 143 and 14 bp in size.
3-13: Enriched PCR ofWGLF DNA.
14: negative control cut with BstNl.
A Ki-ras codon 12 mutation can clearly be seen in lane 8 (arrowed).
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Figure 6.2 Polyacrylamide gel electrophoresis of enriched PCR for the
detection ofp53 codon 248 mutations
Lanes: M: Marker DNA (1 Kilobase ladder; Life Technologies Inc. [Gibco
BRL])
A: uncut PCR product
B: Msp I digested positive control
C: mutant-enriched positive control
D: Msp / digested negative control
E: mutant-enriched negative control
F and H: Msp I digested tumour DNA from paraffin sections
G and I: mutant-enriched PCR of corresponding WGLF showing mutations.
Products ofamplification and digestion have been resolved on 15%
polyacrylamide gel. Mutant alleles remain undigested as a single 143 bp
product. Wild type alleles are cleaved into 58- and 85 bp products.
Enriched-PCR control reactions show how mutant alleles can be selectively
amplified. This example shows the two p53 mutations successfully detected in
WGLF DNA.
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amplified for further analysis and in the second despite PCR amplification only the wild
type signal was detected on SSCP.
For APC 15 mutations in the MCR were detected in the normal / tumour pairs
however none of these could be detected by SSCP analysis of the whole gut lavage
fluid DNA. In 10 cases no PCR amplification occurred in 5 no SSCP was identified
despite PCR amplification (figure 6.3).
6.4 Discussion
By the analysis of the four mutation sites described, 18 (45%) patients had the
potential for a genetic diagnosis of their malignancy. This is lower than expected even
allowing for the inefficiencies of SSCP and the fact that only Ki-ras codon 12, p53
codon 248 and the MCR ofAPC were analysed. This low number of mutations can be
explained by the following reasons. The study population is small and as such there may
be a degree of sample bias reducing the overall number of mutations. Regional variation
may also produce differences in the number ofmutations when our Scottish population
is compared to other published series. Projection from one population base to another
may not be entirely accurate. I have already shown the frequency of TGFfi RII
mutations in the Scottish population is lower than that published for other populations.
When extracting DNA from paraffin sections the cancer was not microdissected and
so the samples will inevitably contain some normal DNA. The sensitivity ofmutation
detection is reduced by not microdissecting and thus some mutations will fail to be
detected. It has been shown that the more sensitive the technique employed the more
mutations are detected (Carpenter 1996). SSCP is regarded as less sensitive than
other established mutation detection techniques and the use of SSCP may have lead to
an underestimation of the number ofAPC MCR mutations. The overall low number of
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Figure 6.3 An autoradiograph of the SSCP analysis ofAPC in two whole gut
lavage fluid samples.
Autoradiograph of y33P ATP labelled PCR products resolved on 50% MDE gel by
SSCP.
N: normal DNA from paraffin section
T: tumour DNA from paraffin section
W: WGLF DNA from corresponding cancer patient
Extra bands representing APC MCR mutations (arrowed) can be seen in the
tumour DNA in each of these two examples. The corresponding WGLF DNA
samples only show the normal pattern.
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mutations that were detected in cancer DNA from paraffin sections does, however,
highlight potential limitations imposed on any ultimate screening strategy. By confining
our interrogation to known mutations for each site examined a proportion ofmutations
will not be identified thus limiting the overall effectiveness of the screening strategy.
Notwithstanding, these limitations, as a proofof principle, further examination ofwhole
gut lavage fluid DNA is still valid. Interrogation of cancer DNA from paraffin sections
determines the denominator by which whole gut lavage fluid DNA analysis can then be
assessed.
Only 4 mutations were detected in the whole gut lavage fluid DNA, and so a genetic
diagnosis was only possible in 10% of the study population by whole gut lavage fluid
examination. For Ki-ras and p53, failure to detect mutations was largely attributable to
the failure in DNA amplification from the whole gut lavage fluid sample. Previous
studies examining Ki-ras and p53 in stool have all experienced PCR inhibition reducing
the number of samples available for genetic examination (Sidransky 1992; Tobi 1994;
Hasegawa 1995; Smith-Ravin 1995; Cruickshank 1996; Nollau 1996; Villa 1996) . In
this study, although high copy number DNA suitable for amplification was identified in
93% of the whole gut lavage fluid samples, single copy genes could be amplified by
PCR in only half of these samples. There was no significant difference in the amount of
DNA in those samples that amplified and those samples that would not. This suggests
that PCR inhibition is not a significant problem with whole gut lavage fluid samples
when amplifying genes of high-copy number, but may be problematic when studying
single-copy genes. In addition, although human DNA is estimated to account for 10%
of the total DNA extracted from stool (Hasegawa 1995) many samples in this study
were lost to further examination presumably because there was insufficient human DNA
available for satisfactory amplification of single copy genes. In those that did amplify,
identical mutations were found in both tumour and whole gut lavage fluid samples
when compared by direct sequencing (figure 6.4).
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Figure 6. 4 Sequence reaction for whole gut lavage fluid sample in which p53
mutation was detected by enriched PCR
N: normal control DNA from paraffin section showing normal sequence.
W: WGLF DNA. Enriched PCR ofWGLF DNA showing mutant sequence. The
DNA used for this sequencing reaction was obtained from an enriched PCR
amplification. The mutant band was cut from a polyacrylamide gel and the DNA
extracted by boiling it in deionised water. The extracted DNA was then amplified
using a nested 3' primer and this product was then sequenced.
T: tumour control DNA from paraffin section of tumour resected from the same
patient from which sample W was obtained.
Sample T shows a G to A substitution mutation at the third base pair of codon 248
(arrowed). Some residual normal sequence remains because ofnormal stromal
tissue contaminating the tumour DNA.
Sample W shows the identical mutation in DNA obtained from WGLF taken
preoperatively from the same patient. This mutation was successfully isolated by
enriched PCR techniques.
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PCR amplification ofwhole gut lavage fluid DNA for APC was less successful than
for Ki-ras possibly because the product size was larger (approx. 220 bp compared to
143 bp). For APC and TGFfi RII it was not possible to identify any mutations even
when PCR amplification was successful (fig 6.3). Mutations in the whole gut lavage
fluid samples were only detected after selective enrichment permitting detection of 1
mutant in 104 wild type alleles (Kahn 1991). All the previous studies examining Ki-ras
mutations in stool have employed an enrichment strategy (Sidransky 1992; Tobi 1994;
Hasegawa 1995; Smith-Ravin 1995; Cruickshank 1996; Nollau 1996; Villa 1996) . One
study had limited success employing SSCP to identify p53 mutations in the stool of
known colorectal cancer patients. However these were all advanced cancers and FOB
testing on the same patients was four times more accurate (Eguchi 1996). I found
SSCP to be insensitive when examining whole gut lavage fluid samples. On control
DNA I was able to detect only 1 mutant in 50 wild type alleles for APC and 1 in 20 for
TGFfi RII. The sensitivity of the TGFfiRII assay is compromised by Iaq slippage
which produces artificial deletions in the polyadenine repeat sequence in wild type cell
lines reducing the fidelity of the PCR amplification (Parsons 1995b).
Since the experimental work for this thesis was undertaken researchers have
demonstrated that APC mutations have been detected in stool samples of colorectal
cancer patients (Deuter 1998). Once again an enrichment technique was required. In a
sample of 23 patients, 21 Ki-ras, p53 and APC mutations were detected in 13 different
cancers. Thus 56 % of patients in this study had the potential for the genetic diagnosis
of their colorectal cancer. Some 11 tumours showed Ki-ras and p53 mutations by direct
sequencing. Direct sequencing of the stool samples detected three point mutations in
two stool samples (compare to work presented in this thesis). Examination of the MCR
ofAPC in tumour DNA detected only five mutations in 23 cancers using a
heteroduplex technique (i.e. 22 % which is much less than might expected). Initial
heteroduplex analysis of the corresponding stool DNA failed to detect mutations due to
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a high a background contamination ofwild type DNA. However when the region of the
gel that contained the putative heteroduplex DNA was excised and this DNA subjected
to further PCR amplification, subsequent heteroduplex analysis successfully
demonstrated the expected mutation in all five cases. This technique relied on prior
knowledge of the positions on mutant heteroduplex DNA by analysis of the resected
tumour DNA, and hence is not practicable for screening purposes. The authors suggest
this problem could be overcome by exercising larger portions of the gel to encompass
all possible mutation harbouring DNA fragments. DNA extracted from this excised
segment of gel could then be subjected to a second mutant enriching PCR amplification
and further heteroduplex analysis.
The identification of a Ki-ras mutation in one whole gut lavage fluid sample but not
the tumour may represent detection of neoplastic cells not represented in the paraffin
section. Repeated analysis ofDNA from the paraffin section failed to show any Ki-ras
mutation. Multiple Ki-ras mutations are found in tissues of nearly half of patients with
colorectal cancer containing Ki-ras mutations indicating that distinct evolutionary
subclones may be involved in the development of tumour in some patients (Zhu 1997).
Other studies have shown the heterogeneous nature ofKi-ras mutations in adenomas
sampling an adenoma at only one site revealed a mutation in 38% of cases but this
increases to 57% if two site from the same adenoma were examined (Saraga 1997). In
15% of cases the two sites examined contained different Ki-ras mutations. It is
presumed that the paraffin section in my study did not contain the subclone of cells with
the Ki-ras mutation detected in the whole gut lavage fluid DNA. This demonstrates the
potential of such a sampling technique to contain DNA that represents the entire
colonic mucosa rather than an small macroscopically abnormal section of colonic
mucosa. Subsequent colonoscopy in this individual did not identify any synchronous
lesions. A Ki-ras mutation in colonic effluent from a macroscopically normal colon has
been noted previously (Tobi 1994) and was felt to highlight the potential of
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premalignant detection by genetic tests. With the advent ofmore sensitive techniques
for mutation detection it is now clear that Ki-ras mutations occur at high frequency in
the microscopically normal tissue adjacent to carcinomas and adenomas containing Ki-
ras mutations suggesting these mutations might be useful markers for early detection of
colorectal cancer (Zhu 1997).
These findings show that whole gut lavage fluid is suitable for PCR analysis but its
usefulness as a screening resource is still limited because in many samples examination
of single copy genes is not possible. The finding that enriched techniques are required
highlights the fact that wild type DNA is vastly in excess of any mutant DNA. This
reduces the overall sensitivity of any method that is employed for mutation detection
and will undoubtedly mean mutations that are present will be underestimated by being
lost in a background "noise" ofwild type DNA. For successful identification of
mutations commonly associated with colorectal cancer in the whole gut lavage (or
stool) from colorectal cancer patients, a method that selectively enriches for the
mutation must be employed. At present, this limits detection to point mutations at fixed
known sites, for example Ki-ras codons 12 and 13 andp53 codons 175 and 248. By
using increasingly sensitive techniques such as radiolabelled hybridisation or
fluorescence PCR (Carpenter 1996) and improving sample collection to reduce PCR
inhibition, the detection of such point mutations could approach 100%. However,
successful analysis at these four sites would still only have the potential to detect
approximately 60% of colorectal cancers (Bos 1987; Nigro 1989; Hollstein 1991). This
detection rate is no better than present FOB testing and, as such, severely limits the
potential for early colorectal cancer diagnosis by genetic tests. Given current
technology and knowledge of the mutations associated with colorectal cancer, it seems
unlikely that genetic techniques offer any advantage over existing screening methods.
For such tests to be usefully employed as screening tests, either a new point
mutation that occurs at high frequency in colorectal cancer must be identified, or other
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methods that enrich for unknown mutations must be developed. Possible alternative
strategies include the detection of cancer specific mutations in the plasma or serum of
patients with colorectal cancer. Ki-ras mutations have been detected in DNA extracted
from the plasma of patients with colorectal cancer, in a small study of 14 patients with
colorectal cancer. Anker and colleagues demonstrated that using mutant allele specific
primers 7 cancers had Ki-ras codon 12 mutations and the same mutation could be
detected in 6 (86%) of the plasma samples. However these included only one Dukes'
stage A cancer and 5 Dukes' stages C and D suggesting mutant DNA in the plasma is a
late phenomenon limiting its diagnostic and screening use (Anker 1997). This is also
borne out by two other studies in which mutant DNA was detected in the serum of
patients with head and neck cancer and the plasma of patients with lung cancer but only
in patients with advanced stage disease (Chen 1996; Nawroz 1996). Splicing variants of
the mRNA for the transmembrane glycoprotein CD44 have also been detected in stool
sample of patients with cancer. Variant 6 and variant 10 mRNA was detected in 17 of
25 (68%) of stool samples obtained preoperatively from colorectal cancer patients.
Successful detection was not dependent on stage of the cancer but was influenced by
position of the lesion. Rectal and sigmoid lesions were more easily detected than right
sided lesions. CD44 variant expression occurs in a variety of tissues and is also seen in
ulcerative colitis and Crohns disease. The source of the variant mRNA in this study was
unknown (as colonic cancer cells were not cytologically identified) and may have
originated other sources such as from activated lymphocytes (Yamao 1998). Another
possibly more promising area of progress lies in the determination that almost 95% of
colorectal cancers exhibit telomerase activity (Odogwu 1997). This allows potential
screening tests to focus on a single molecular abnormality for examination with the
potential for increases in sensitivity and specificity.
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7. Telomerase
As discussed in the introduction the detection of telomerase activity may represent a
single molecular test which could be used for the early detection of colorectal cancer.
The telomeric repeat amplification protocol (TRAP) (Kim 1994) can detect telomerase
activity in as few as 10 - 100 cells. (An oligonucleotide primer acts as a substrate for
telomerase extension, the products then serve as templates for PCR amplification.)
Combined results on the detection of telomerase activity indicates a specificity of 91%,
sensitivity of 85%, a positive predictive value of 93% and a negative predictive value of
81% (Kim 1997). Telomerase activity has been detected in 55% of voided urine
samples from patients with bladder cancer and 84% ofbladder washouts from the same
patients (Kinoshita 1997) and also in 60% of lumenal washings from resected colorectal
cancers (Yoshida 1997) although these were obtained artificially by perfusing the
resected specimen with saline until it ran clear before obtaining the sample for analysis.
This finding does however highlight a potential use for whole gut lavage fluid in
detecting telomerase activity. There are no studies detecting telomerase activity in
stool.
Six patients from the original study group had whole gut lavage fluid stored -70°C.
These samples were used to see if telomerase activity could be detected in whole gut
lavage fluid obtained from patients with colorectal cancer.
Methods and Results
All experiments utilised the PCR-ELISA TRAP assay (Beohringer-Manheim), (see
materials and methods). All assays contained a manufacturer provided positive control
the kidney cell line (kidney 293). A negative control was produced by heat inactivating
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the positive control. Using frozen normal and tumour tissue from archived colorectal
cancer cases protein extraction was performed as described in the manufacturers
protocol. These protein extracts were then subjected to the PCR-ELISA TRAP assay.
Several experiments were required to optimize the reaction conditions, particularly the
PCR portion of the assay. Optimum conditions are detailed in the materials and
methods. These reaction conditions were then used for all subsequent reactions. Each
reaction was performed in duplicate as were absorption readings. Mean absorption
readings with standard errors have been plotted in the histograms.
Next, the limit of sensitivity of the assay was assessed. Telomerase extracted from
the cancer cell line HT 29 which exhibits telomerase activity was compared to the kit
control assay. Doubling dilutions were performed from an initial protein concentration
equivalent to 500 cells. Two sets of doubling dilutions were performed firstly with
DDW and secondly with PEG at a concentration (59 g/L). A doubling dilution effect
was noted with DDW dilution. It was possible to detect telomerase activity at protein
concentrations equivalent to 62 cells (fig 7.1). However, all the PEG diluted reactions
were negative.
To evaluate the effect ofPEG on the PCR a Ki-ras PCR as previously described was
performed on control DNA. To a series of reactions a doubling dilution ofPEG was
added starting from a concentration 59 g/L. The PCR products were resolved on a 2%
agarose gel. The results showed that PEG inhibited any PCR amplification down to a
16 fold dilution (3.69 g/L) (figure 7.2). A second PCR assay was then performed
focusing on PEG concentrations around 3.69 g/L). PCR amplification was achieved
with a PEG concentration of 4.72 g/L or less which represents a 12.5 fold dilution of
whole gut lavage fluid. Subsequent TRAP assays containing HT 29 cells and PEG
concentrations of 4.7 g/L produced satisfactory ladder patterns on silver stained MDE
gels when the PCR products were resolved and positive ELISA results again down to
protein extract equivalent to 62 cells.
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Next the whole gut lavage fluid from six patients with known colorectal cancer was
analysed. In each case unfiltered processed samples had been snap frozen and stored at
-70°C and were analysed following initial protein concentration determination. With
telomerase being an intracellular protein, unfiltered whole gut lavage fluid samples were
therefore required for analysis. It was elected to perform the initial analysis on
unfiltered, unprocessed whole gut lavage samples. TRAP assays were performed on
aliquots containing 50 mg and 25 mg total protein from each lavage sample. Each
sample was diluted to adjust the final PEG concentration in the PCR to 4.7 g/L and
then subjected to TRAP ELISA analysis. No telomerase activity was detected in any of
the samples (figure 7.3).
Finally one of the whole gut lavage fluid samples was spiked with HT 29 protein
extract in doubling dilutions from a protein extract with an initial concentration
equivalent to 1000 cells. PCR-ELISA analysis of this series of samples was also
negative in all cases (figure 7.3).
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Figure 7.1 Telomerase PCR ELISA absorption readings for doubling dilutions
of positive control cell line kidney 293
Absorption: A450nm - A630nm
Error bars represent standard errors
A positive assay was assumed if an absorption reading of
> 0.5 A450 - A630 was obtained
Hence it can be seen that this assay can reliably detect telomerase activity
in the protein cell lysate equivalent to 62 cells.
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Figure 7.2 PEG inhibition of a Ki-ras PCR on an unrelated positive control
DNA
Ml 23456789 10
Ki-ras PCR amplification with doubling dilutions ofPEG (initial concentration
59 g/1) in reaction mixture. Products have been resolved on a 2% agarose gel,
stained with ethidium bromide and viewed under ultraviolet light.











It can be seen that concentrations of PEG >12.5% completely inhibit PCR
amplification. A further experiment showed that PEG concentration of 10% or
less allowed successful PCR amplification.
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Figure 7.3 Telomerase PCR ELISA absorption readings for whole gut lavage
fluid from a cancer patient and whole gut lavage fluid with 1000 cell equivalents
of positive cell line HT29 added.
Error bars represent standard errors
Absorption: A450nm - A630nm
Sample
1 Positive Control
2 50mg WGLF Protein
3 25mg WGLF Protein
4 50mg WGLF+ 1000 Cell equivalents HT29
5 50mg WGLF + 500 Cell equivalents HT29
6 50mg WGLF + 250 Cell equivalents HT29
7 50mg WGLF + 125 Cell equivalents HT29
8 50mg WGLF + 62 Cell equivalents HT29
9 50mg WGLF + 37 Cell equivalents HT29
10 50mg WGLF + 18 Cell equivalents HT29




In this small series no telomerase activity was detected in the whole gut lavage fluid
samples. Unfortunately, no frozen tumour tissue was available for analysis from these
samples to confirm the presence of telomerase activity in the original tumour. Given the
fact that at least 90% of colorectal cancer exhibit telomerase activity (Odogwu 1997;
Shay 1997) one could reasonably assume 5 of the 6 samples studied would exhibit
telomerase activity.
The concentration ofPEG in the PCR is important with concentrations above 4.7g/L
significantly inhibiting the PCR. It is possible that despite dilution there was still an
inhibitory concentration ofPEG in our samples. PEG solutions have been shown to
interfere with ELISA detection of tumour associated antigens in whole gut lavage fluid.
This inhibitory effect is thought to be due to PEG interfering with antibody binding to
the plastic ELISA plates. This inhibitory effect shows an inverse exponential correlation
with increasing PEG concentrations and PEG concentrations below 12 g/L do not
significantly affect results (Tobi 1991). The PEG concentration in my samples was
diluted to below 4.7 g/L and so will have minimal influence on the results. In our
laboratories when assaying for human immunogloblins in PEG derived whole gut lavage
fluid, pre-coating the microtitre plates with antiserum to human immunoglobulin prior
to adding the lavage avoids this PEG interference (O'Mahony 1990). Development of
an antiserum to telomerase that could be used in a similar manner may improve the
assay sensitivity and could prove to be useful avenue of further research.
The proportion of cancer cells compared to normal stromal cells within a cancer
specimen affects the telomerase activity detected when compared to pure cancer cell
lines as a control. This relationship is linear. Prostate cancers (that only contained 5%
of cancer cells when examined histologically) demonstrated significantly less telomerase
activity when compared to colorectal cancers and sarcomas which showed 30% and
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65% tumour cell infiltration (Engelhardt 1997). The findings in section 3 have
demonstrated that cancer cells are an infrequent finding in whole gut lavage fluid and it
may be that telomerase activity in whole gut lavage fluid samples is beyond the limit of
the TRAP assay sensitivity either because of the dilution required for optimal PEG
concentration or because the proportion of cancer cells to normal cell is too low.
While dilutional factors may play a role even whole gut lavage fluid samples spiked
with cells known to exhibit telomerase activity, at a concentration that should be
detected, also produced a negative assay. This suggests some other confounding factor.
Telomerase is known to be extremely sensitive to inactivation by heat and RNase
(Morin 1989). It is possible that heat inactivation occurred before the samples were
frozen at -70°C. This is however require the samples to be heated to greater than 50°C
and is therefore unlikely. The whole gut lavage fluid samples used in this study were
unfiltered and unprocessed and telomerase inactivation by bacterial or endogenous
RNase could have occurred. Intestinal secretions contain proteases which can effect the
analysis of immunoglobulins and the addition of protease inhibitors may reduce
immunoglobulin loss from gut lavage samples (O'Mahony 1990). These proteases
could also lead to telomerase degradation. This suggests that modification of the
collection ofwhole gut lavage fluid to include an RNase inhibitor and possibly trypsin
inhibitors, as used in processed whole gut lavage samples for immunoglobulin assays,
might enhance telomerase activity detection in these samples.
One study has detected telomerase activity in lumenal washings from cancer
specimens (Yoshida 1997). These samples were artificially obtained in the laboratory.
My work described above has shown the fragile nature of telomerase and the fastidious
assay required for its detection limits the detection of telomerase activity in the clinical
samples presently available. Further developments as indicated above will be required
before a reliable clinical test of telomerase activity is available.
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8. Mutational analysis of synchronous colorectal cancers
It was hoped that the hypothesis ofAPC mosaicism could be explored by using
whole gut lavage fluid to obtain cytological samples from the entire colonic epithelium
in individuals known to be at high risk for colorectal cancer. Unfortunately, I have
shown present methods ofAPC mutation detection are not sensitive enough to detect
mutations in DNA obtained from whole gut lavage fluid.
A proportion of patients with colorectal cancer present with two primary colonic
cancers (synchronous cancers). In these, individuals one could reasonably expect an
increased cancer risk. Individuals with an increased risk of colorectal cancer may be
mutational mosaics for APC which predisposes them to cancer (Dunlop 1996b). It has
also been noted that the overall prognosis for patients with synchronous lesions is very
poor when compared to sporadic and metachronous cases (Bekdash 1997). Also the
frequency ofKi-ras mutations is lower in patients with synchronous cancers than in
sporadic cancers (Hayakumo 1995). These findings suggest tumourigenesis for
synchronous cancers may be different to sporadic lesions. Assuming APC acts as a
gatekeeper for the development colorectal cancer (Kinzler 1996), patients with APC
mosaicism may be more likely to acquire multiple cancers (either synchronous or
metachronous). Colonic epithelial APC mosaicism may therefore play a role in the
tumourigenesis of synchronous cancers. The broad spectrum of known APC mutations
in colorectal cancer (summarised in Cunningham 1996) and the large size of the gene
(Groden 1991) mean that identical APC mutations in synchronous colorectal cancers
would be highly suggestive ofAPC mutational mosaicism rather than a chance finding.
The demonstration of identical APC mutations in synchronous tumours would thus
provide strong support for the mosaicism theory. To further pursue this hypothesis I




The pathology reports of all individuals undergoing colonic resection for cancer in
one teaching hospital for the period 1989 to 1996 were scrutinized. Patients with a
report indicating synchronous cancers were identified. A search of the histological
archive, tissue and DNA stores was then undertaken to retrieve material suitable for
DNA analysis.
DNA was prepared from either frozen tissue stored at -70°C or extracted from
paraffin blocks. (Section 2.3).
APC mutations were detected using the protein truncation test (figure 8.1) for DNA
extracted from frozen tissue (Prosser 1994) or single strand conformational
polymorphism for DNA extracted from paraffin sections (Cooper 1996). Microsatellite
instability analysis was undertaken by exploring the microsatellite sequences at D2S123,
D5S346, D13S160, and BAT40 (Liu 1995; Dunlop 1996). These sites were chosen
because the have been used in other published work to determine RER status and
because they are sites with which our laboratory is particularly familiar. Evidence of
chromosomal instability rather than microsatellite instability was sought by loss of
heterozygosity (LOH) for APC and tumour DNA ploidy. For LOH ofAPC two known
polymorphic sites were analysed by restriction fragment polymorphism; the 3'
untranslated region and exon 11 (Curtis 1994) (figure 8.2). An assessment of tumour
ploidy was performed by Mr. Robert Morris. This was performed on either fresh tissue
stored at -70°C or tissue taken from 10 pm paraffin sections (Vindelov 1983). The
nuclei were stained with propidium iodide and analysed by flow cytometry (EPICS,
Coulter Ltd. Beaconsfield, Bucks UK).
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Results
A total of 17 (4 %) patients were identified from the records of 424 patients who
underwent surgical resection for cancer in the study period. Of these 17 patients only
12 had archive material available that was suitable for DNA analysis. These 12 formed
the study population. There were 11 cases with two synchronous tumours and 1 with
three. In all 25 tumours were analysed. The mutations that were detected are
summarised in table 8.1.
Of the 25 tumours 10 demonstrated an APC mutation. Two individuals had an APC
mutation in both of their cancers, 6 had an APC mutation in only one of the tumours
examined and 4 had no mutations detected in any of their cancers. In no case however
were identical APC mutations detected in the same individual.
There were 5 cancers that demonstrated an RER+ phenotype, and a further 4 which
demonstrated MIN at only one locus of the 4 tested. Thus 20% of cancers
demonstrated an RER+ phenotype and 36% of cancers demonstrated MIN at one or
more locus. All the RER+ cancers occurred in 2/12 patients (16.7%). MIN in at least
one locus was seen in 4/12 patients (33%). One individual with 3 cancers showed
RER+ phenotype in two cancers, the third cancer was unstable at one locus only. In a
second individual both cancers were RER+. In a third patient both cancers
demonstrated MIN at one locus only. One individual had one cancer which was RER+
and one which did not show any MIN. In two other patients one cancer showed MIN at
one locus and the other did not demonstrate MIN. Two cancers demonstrating MIN at
one locus also had an APC mutation identified in the MCR. (Table 8.1)
Cancers exhibiting RER+ phenotype did not have any APC mutations in the MCR.
Similarly only two cancers that showed MIN at one locus had an APC mutation in the
MCR (Tables 8.2 and 8.3). These differences did not reach statistical significance
(Fishers exact test).
119
Figure 8.1 Protein truncation test for APC mutations in normal and cancer
tissue from a patient with synchronous colonic cancers
N T1 T2 Leu
In all three lanes (N, T1 and T2) the normal protein product can be easily
identified (solid arrow). In sample T1 there is also an additional faster migrating
band indicating a truncated mutated protein product. This product is not seen in
lane T2 (open arrow). A leuciferase control reaction was included in all protein
truncation experiments to confirm successful translation and transcription. The
smaller protein fragments in Leu represent protein degradation as a result of
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Table 8.2 Relationship between RER phenotype and APC mutations in 25
cancers from 12 patients with synchronous cancers.
APC mutation present APC mutation absent
RER + 0 5
RER- 10 10
Not significant p = 0.0613 Fisher's exact test
Table 8.3 Relationship between MIN phenotype and APC mutations in 25
cancers from 12 patients with synchronous cancers
APC mutation Present APC mutation absent
MIN + 2 7
MIN - 8 8
Not significant p = 0.2290 Fisher's exact test
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Aneuploid cancers were identified in 4 cancers in 3 patients. In one patient both
cancers were aneuploid. In this patient no APC mutations were identified, there was no
microsatellite instability or loss of heterozygosity. In the second patient one cancer
exhibited aneuploidy. This cancer also had an APC mutation detected and exhibited
LOH at the 3' UTR and exon 11. No MIN was detected. The second cancer in this
patient showed no mutations, LOH or MIN. In the third patient the aneuploid cancer
also had a mutation identified in APC but did not show any LOH or MIN. The diploid
cancer showed LOH at the 3' UTR but no MIN or APC mutation.
No cancers exhibiting an RER+ phenotype displayed LOH or aneuploidy. These
differences were not statistically significant (Fishers exact test p > 0.99).
Discussion
In this series 4% of patients with colorectal cancer had a synchronous cancer which
is in keeping with other reports where synchronous cancers account for 2.5 - 3.9% of
patients with colorectal cancer (Fante 1996; Bekdash 1997). In our series APC
mutations show no concordance, strongly suggesting synchronous colorectal cancers
occur as individual events with regard to APC. Only 6% of synchronous colorectal
cancers show concordant Ki-ras and p53 mutations in both lesions (Koness 1996),
supporting the conjecture that synchronous colorectal cancers are the result of
independent events. Ki-ras mutations are confined primarily to two codons (Bos 1987)
and the majority ofp53 mutations are clustered around mutation hot spots (Hollstein
1991). It is therefore conceivable that concordant Ki-ras and p53 mutations in
synchronous cancers could result in independent cancers by chance. The low incidence
of concordant Ki-ras and p53 mutations merely strengthens the support for
synchronous cancers arising independently. In APC the large range of reported
mutations and the size of the gene preclude the possibility of the same mutations
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occurring by chance. Patients with advanced rectosigmoid adenomas are more likely to
have advanced proximal adenomas or cancers than patients with early recto-sigmoid
lesions (Papatheodoridis 1996) implying independent cancers with differing mutational
profiles could arise from a common environmental insult. Analysis ofKi-ras and p53
mutations in six primary cancers occurring in one individual showed each cancer to
manifest the genetic characteristics typical of the tissue of origin suggesting the
synchronous primary cancers arose independently and progressed along different
carcinogenic pathways (Herring 1996). The evidence from multiple gastric cancers
would appear to be conflicting. In one study multiple gastric cancers show discordance
for APC, MCC, andp53 mutations indicating independent origin for synchronous
gastric cancers (Kang 1997). Other work analyzing synchronous gastric cancers has
shown identical p53 and c-erbB2 status in 66% of patients with multiple synchronous
gastric cancers suggesting precancerous lesions arise from conditions leading to similar
genetic alterations (Wittekind 1997).
Patients with HNPCC are four times more likely to acquire a metachronous cancer
than patients with sporadic colorectal cancer. The second malignancy occurring on
average 8.7 years after the first (Fante 1996). HNPCC patients have a defect in their
DNA mismatch repair system (Lynch 1993) and are thought to acquire mutations in key
genes related to carcinogenesis at an increased frequency (Kinzler 1996). They may
therefore also be at an increased risk of synchronous cancers (Dunlop 1996). In the
reported series an RER+ phenotype was present in 16.7% of patients. MIN was
demonstrated at 2 or more loci in 20% of cancers and 1 or more locus in 36% of
cancers. Bubb et al. in a large series of 219 sporadic cancers that included 4
synchronous cancers demonstrated MIN at 2 or more loci in 10.5% of cancers and
MIN at 1 or more loci in 17.8%. (Bubb 1996). This difference, when compared to the
series reported here, could represent sample bias in the small population considered. It
could equally indicate a predisposition to an RER+ phenotype similar to that noted in
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Figure 8.2 Loss of Heterozygosity for the 3' untranslated region oiAPC.
NT NT
The 3' untranslated region of the APC gene contains an Sspl polymorphism.
For each sample normal and tumour pairs were amplified by PCR. These
products were then subjected to Ssp I enzyme digestion. The products were
then resolved on 3% agarose gels. For each sample after enzyme digestion
there is a constant 580 bp band. The two alleles are 270 bp and 135 bp in size.
The above gels shows a representative samples.
The left hand normal/tumour pair shows an informative sample with no LOH.
The right hand normal/tumour pair shows an informative sample with the
tumour sample showing loss of the 135 bp allele (arrowed).
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patients with attenuated extracolonic manifestations (Dunlop 1996). This in turn could
indicate that patients with synchronous colorectal cancers have an underlying germline
MMR deficiency. The small sample size in my study limits the power of any analysis
and differences in mutational profiles failed to reach significance. The small sample size
when analyzing synchronous cancers is principally limited by the availability of cases. In
my study based in a centre with a strong interest in colorectal cancer and molecular
genetics with a large archive ofDNA, there was still only 12 cases available for detailed
analysis. Pooling of samples from other centres would seem to be the only feasible
method by which to get a suitable sample size.
Consequently, there are few studies examining RER phenotype in synchronous
cancers. Multiple primary cancers (cancers occurring in different organs at the same
time) have been studied. An RER+ phenotype can be detected in at least one cancer in
89% of patients with multiple primary cancers (however only one patient had multiple
colorectal cancers) but only 11% of patients with a single primary cancer (Horii 1994).
Patients with independent multiple gastric cancers also have a higher prevalence of
MIN than solitary cancers 65% versus 24% (Shinmura 1995). The proportion ofRER+
cancers in our study is not as high as the aforementioned studies. In patients with
multiple primary cancers the cancers analysed were in a wide range of tissues and this
population is more in keeping with the characteristics ofLynch's Syndrome type II
which is known to have a high incidence ofRER+ phenotype (Lynch 1993). Thus these
populations are very different from our own purely synchronous colorectal cancer
population. As such, these studies may have study populations biased towards an RER+
phenotype. Metachronous tumours have a greater frequency ofmicrosatellite instability
than sporadic colorectal cancer (Sengupta 1997) suggesting an underlying defect in
their mismatch repair system. RER screening may be potentially useful in identifying
patients at increased risk of additional primary cancers (Horii 1994).
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Although not statistically significant there is a tendency for the cancers in this study
to have either an APC mutation or an RER + phenotype (Table 8.2). This suggests
there might be two mutually exclusive pathways for colorectal carcinogenesis. IfAPC
mutations are the initiating event in the pathogenesis of both RER - and RER + colon
cancers then, the pattern and type ofmutation should be the same in both types of
cancer. If, however, genomic instability is the initiating event in the pathogenesis of
RER + cancers, differences in their APC mutations when compared to those in RER -
tumours would be expected. One might expect a decreased frequency of a allele loss at
APC might occur in RER + tumours. Similarly more frame shift deletions than nonsense
mutations would be expected. Also, mutations in APC in RER + tumours should tend
to occur in stretches of simple repeat sequences. Previous experiments have shown that
the spectrum ofAPC mutations differs between RER + and RER - cancers. Huang et
al. showed that in 19/52 RER+ cancers that came from kindreds fulfilling the
Amsterdam criteria for HNPCC RER+ cancers had a significant increase in frameshift
mutations when compared to non-RER tumours suggesting the RER phenotype
precedes and is responsible for the APCmutation (Huang 1996). In a separate study
examining sporadic cancers there was no evidence that sporadic RER + and RER -
colon cancers differed in their frequency of allele loss at APC, the overall frequency of
APC mutations, or their frequency of framed shift APC mutations (Homfray 1998).
Homfray concluded that in sporadic RER + and RER - colon cancers, APC mutations
initiate tumourigenesis; mismatch repair becomes defective in sporadic RER + tumours
at a later stage. It remains possible that MMR mutations initiate the growth of some
tumours, but that its effect at such a stage would be to confer a selective growth
advantage; an RER + phenotype and APC mutations would then occur later (Homfray
1998).
Although there were no identical APC mutations in this series I have shown there is
a predisposition to a RER+ phenotype when compared to another series examining
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sporadic colorectal cancer (Bubb 1996). It is possible that the actual mutations in APC
might arise from a common mechanism (e.g. defective MMR) albeit in different parts of
the gene. Attempts were made to characterise the MCR mutations detected in the study
population by fluorescence sequencing but this was limited by the available time. Four
mutations were confidently identified and two were indeed 2 base pair deletions from
an AG5 repeat in the MCR (nucleotides 4388 to 4395 (Groden 1991)). This mutation
has been previously described in association with RER+ cancers and HNPCC (Huang
1996).
In the reported series the majority of cancers were diploid which is a known feature
ofHNPCC (Lynch 1993). In a small series examining cancers with synchronous
adenomas, evidence of cytogenetically related clones in both the cancer and the
adenoma was detected in 5/7 (71%) cases. Furthermore cytogenetic analysis of
hyperplastic polyps showed evidence of cytogenetic changes in only 37.5%. These data
suggest that for cancers and adenomas these otherwise macroscopically distinct lesions
either arose as part of the same neoplastic process or that the same oncogenic
environmental factor induced identical chromosomal rearrangements in more than one
cell (Bardi 1997).
In summary I detected no evidence ofmutational mosaicism with respect to APC in
the region analysed. When compared to another large series of sporadic colorectal
cancer there was an increased incidence ofRER+ cancers and MIN cancers in
synchronous cases. The majority of cancers were diploid in character. These
observations could indicate an underlying MMR deficiency. In conclusion synchronous
cancers appear to arise in unstable epithelia in response to a common environmental
insult but then progress down different genetic mutational profiles.
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9. Final Discussion
The principal aim ofmy research was to capitalize on other preliminary work to
devise a genetic method specific for detecting colorectal cancer from exfoliated lumenal
cells obtained from whole gut lavage fluid. If successful, it was envisaged such a test
may have practical applications in the field of colorectal cancer screening. Secondly, it
was hoped that the technique would provide a useful research tool for studying
colorectal carcinogenesis. One specific question related to colorectal cancer
tumorigenesis that was identified was the possibility ofAPC mutational mosaicism in
patients with an underlying mismatch repair defect.
I have successfully demonstrated that it is possible to use the cells obtained in whole
gut lavage fluid for DNA analysis by PCR based techniques. However, confounding
factors that prohibited further development ofPCR based assays were identified.
Firstly, the vast majority of cells obtained by this method are inflammatory or squamous
cells. Secondly, in half the whole gut lavage fluid samples obtained PCR amplification
was not possible either due to reaction inhibition or insufficient DNA. Repeated
sampling ofwhole gut lavage fluid (as for FOB) may be required to improve the
sensitivity and specificity of stool based genetic tests. Finally, a specific mutation
enrichment strategy is required to identify mutant alleles in a vast excess ofwild type
alleles. The net effect ofmy methodology was to limit DNA analysis to known point
mutations suitable for restriction enzyme enrichment techniques. Analysis ofAPC, a
key gene in colorectal carcinogenesis, was therefore severely limited. Development of
better DNA extraction techniques which allow the use of the protein truncation test for
APC mutation detection may provide a useful line of further research.
Whilst undertaking this period of research the link between TGFfiRII mutations and
RER+ cancers was established. My initial attempts to repeat these assays were
unsuccessful but later published SSCP analysis was easily reproducible. My small series
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confirmed TGFfiRII mutations in a smaller percentage ofRER+ cancers than earlier
work suggested. My figure is, however, in broad agreement with other studies
published subsequently. The predominant mutations encountered in TGFfi RII are 1-2
bp deletions in the A10 segment of exon 3. The nature of this mutation precludes it from
restriction enzyme enrichment techniques.
Another significant advance made while my research was being conducted was the
identification of telomerase activity in up to 90% of colorectal cancers. This is therefore
an obvious target for molecular detection of colorectal cancer eliminating the need to
screen for point mutations at many sites. I was fortunate to be able to include some
preliminary work on telomerase into my research. Telomerase assays are now available
in kit form. Initial validation established the reliability of the commercial TRAP assay.
Application of the TRAP assay to whole gut lavage fluid identified PEG inhibition of
the PCR amplification at high concentrations. Despite correction for this TRAP assay
analysis ofwhole gut lavage fluid was still not possible. The thermoliability of
telomerase and its sensitivity to endogenous RNase activity may have some bearing on
this. Different methods of sample collection and processing may remedy these problems
and therefore offer an opportunity for continuing research.
I was not able to address the question ofAPC mutational mosaicism directly using
whole gut lavage fluid techniques. I therefore turned my attention to the analysis of
synchronous colorectal cancers. The identification of identical APC mutations in
synchronous cancers would be strong evidence in support of such mosaicism. I was
unable to identify single case with identical mutations. This suggests synchronous
cancers develop as result of independent genetic events. There was however a tendency
towards cancers with an RER+ which suggests synchronous cancers may arise in
individuals with an underlying genomic instability for example mismatch repair
deficiency. Further characterisation of the APC mutations in this study population may
support this theory. This does not preclude the possibility that synchronous cancers in
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Forward: 5'- TCA AAG AAT GGT CCT GGA CC
Reverse: 5'- GAC TGA ATA TAA ACT TGT GG
Reaction volume 50pl, primer concentration 0.4pM, Mg2+ concentration 1.5mM
Tm 55°C, annealing time 30 s. 35 cycles.
Cytochrome b
Primer sequences
Forward: 5'- AAA AAG CTT CCA TCC AAC ATC TCA GCA TGA
TGA AA
Reverse: 5'- AAA CTG CAG CCC CTC AGA ATG ATA TTG TCC
TCA
Reaction volume 50pl, primer concentration lpM, Mg2+ concentration 1.5mM
Tm 55°C, Annealing time 1 min. 35 cycles.
Cytochrome oxidase
Primer sequences
Forward: 5'- ACG CCT AAT TCT ACT CCA CCT CAA TC
Reverse: 5ACG ATG TCT AGT GAT GAG TTT GCT A
Reaction volume 50gl, primer concentration lpM, Mg2+ concentration 1.5mM




Forward: 5'- TGG AAC TTC GCT CAC AGG AT
Reverse: 5'-AAG TGG CAG CCT CAA AAG G
Reaction volume 50pl, primer concentration lpM, Mg2+ concentration 3 mM.
Product size 256 bp. Hot Start touch down PCR.
Annealing temp (°C) 63 60 57 55
Annealing time (s.) 30 30 30 30
Cycles 1 1 1 33
APCSSCP section 2
Primer sequences
Forward: 5'-TCA GAC GAC ACA GGA AGC CAG
Reverse: 5GTA CAT CTG CTA AAC ATG AGT GGG
Reaction volume 50pl, primer concentration 0.5pM, Mg2+ concentration 1.5mM.
Product size 294 bp. Hot start, Tm 55°C, annealing time 30 s., 35 cycles.
APCSSCP section 3
Primer sequences
Forward: 5'- CAG GAG ACC CCA CTC ATG TT
Reverse: 5'- CAG CAT TTA CTG CAG CTT GC
Reaction volume 50pl, primer concentration 0.5pM, Mg2+ concentration 1.5mM.
Product size 291 bp. Hot start, Tm 56°C, annealing time 30 s., 35 cycles.
APCSSCP section 4
Primer sequences
Forward: 5'-AGA GTG GAC CTA AGC AAG CT
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Reverse: 5'-CAT TTT CCT GAA CTG GAG GC
Reaction volume 50pl, primer concentration 0.5pM, Mg2+ concentration 1.5mM.
Product size 203 bp. Hot start, Tm 55°C, annealing time 30 s., 35 cycles.
APCPTT segment 2/G2
Primer sequences
Forward: 5'- GGA TCC TAA TAC GAC TCA CTA TAG GGA GAC
CAC CAT GGA GAA CAA CTG TCT ACA AAC T
Reverse: 5'- ATG AGT GGG GTC TCC TG
Reaction volume 50pl, primer concentration 0.5pM, Mg2+ concentration 1.5mM.




Forward: 5'- GGA TCC TAA TAC GAC TCA CTA TAG GGA GAC
CAC CAT GGT TTC TCC ATA CAG GTC ACG G
Reverse: 5'- GAG CCT CAT CTG TAC TTC TGC
Reaction volume 50pl, primer concentration 0.5pM, Mg2+ concentration 1.5mM.





Forward: 5'- TGA CTA CTT TTG ACT TCA GCC
Reverse: 5'- AAC CAT TCA ACA TTT TTA ACC C
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Reaction volume 50pl, primer concentration lpM, Mg2+ concentration 1.5mM.
Product size 120 bp. Tm 50°C, annealing time 30 s. 35 cycles.
BAT 40
Primer sequences
Forward: 5' - ACA ACC CTG CTT TTG TTC CT
Reverse: 5'- GTA GAG CAA GAC CAC CTT G
Reaction volume 50pl, primer concentration lpM, Mg2+ concentration 1 mM.
Product size 109 bp. Tm 50°C, annealing time 30 s. 35 cycles.
D2S123, D5S346, D13S160 CA repeats
Primer sequences
D2S123 Size
Forward: 5' - AAA CAG GAT GCC TGC CTT TA
Reverse: 5'- GGA CTT TCC ACC TAT GGG AC
D5S346 Size
Forward: 5'- ACT CAC TCT AGT GAT AAA TCG GG
Reverse: 5'- AGC AGA TAA GAC AAG TAT TAC TAG TT
D13S160 Size
Forward: 5'- CGG GTG ATC TAA GGC TTC TA
Reverse: 5'- GGC AGA GAT ATG AGG CAA AA
Reaction volume 50pl, primer concentration 0.5pM, Mg2+ concentration 1 mM.
Product size 120 bp. Hot start, Tm 55°C, annealing time 30 s. 35 cycles.
TGFBeta Receptor II Exon 3
Primer sequences
Forward: 5'- CCT CGC TTC CAA TGA ATC TC
Reverse. 5'- TTG GCA CAG ATC TCA GGT CC
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Reaction volume 50jj.1, primer concentration 0.5pM, Mg2+ concentration 2 mM.
Product size 267 bp. Tm 55°C, annealing time 30 s. 35 cycles.
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Protocolfor Polymerase chain reaction optimisation
Volume of each reagent in pL for each optimisation reaction
Reaction
Reagent 1 2 3 4 5 6 7 8
DDW 17 16 15 14 22 21 20 19
dNTP 8 8 8 8 8 8 8 8
Buffer 5 5 5 5 5 5 5 5
Forward Primer 5 5 5 5 3 3 3 3
Reverse Primer 5 5 5 5 3 3 3 3
Mg CI2 2 3 4 5 2 3 4 5
Detergent 3 3 3 3 3 3 3 3
Taq Polymerase 1 1 1 1 1 1 1 1
DNA 5 5 5 5 5 5 5 5
Total 50 50 50 50 50 50 50 50
DDW Distilled Deionosed water
dNTP Nucleotide mixture final reaction concentration of 200 pM
Buffer lOx stock solution diluted to final reaction concentration of




Appendix 2 Study population detailing age, sex, site of lesion, stage
and mutation detection





1 F 60 + + + + SECTION 2 RECTUM A pT2 G2 NO
2 M 85 + DESCENDING B
3 M 81 + + SIGMOID C
4 M 66 + + + + RECTUM A pT2 G2 NO
5 M 73 + + SECTION 1 1 SIGMOID A pTl G2
6 M 63 + RECTUM C
7 M 86 + + SECTION 3 SIGMOID B
8 F 83 + + NO PCR SECTION 1 RIGHT C pT3b NO
9 M 62 + + SECTION 3 RECTUM B pT3b NO
10 M 71 + + - + TRANSVERSE C pT3cG2Nl
11 M 79 + + SECTION 1 1 RECTUM A pT2 NO
12 M 47 DESCENDING D pT3c G3 NO
13 F 74 + + + SECTION 2 RECTUM B
14 F 75 + + + SECTION 4 SIGMOID C pT3b G2 NO
15 F 71 + + SIGMOID C pT3b G2 NO














19 F 72 + + SECTION 1 RECTUM B pT4 NO
20 F 90 + SECTION I RECTUM C pT3b G2 NO
21 M 61 + SIGMOID D pT4G3Nl Ml
22 M 57 + + RECTUM C pT3 G3 NO
23 F 55 + + NO PCR SECTION 1 1 RECTUM C pT3CG3
24 M 73 + + SECTION 1 RECTUM B pT3a G2 NO
25 M 88 + SPLENIC FLEXURE B pT3b NO
26 F 90 + SECTION 1 RECTUM C
27 M 71 + SECTION 4 4 + RIGHT B pT3A NO
28 M 72 + + + TRANSVERSE C pT3bNl
29 M 64 + SIGMOID A pT2 G2 NO
30 M 78 + I RECTUM B
31 M 78 + SPLENIC FLEXURE B pT4
32 F 81 + DESCENDING B
33 F 78 + + + NO PCR SIGMOID C pT3a G2 NO
34 F 67 + RECTUM C pTl
35 M 59 + + NO PCR RECTUM A pT2 G2 NO
36 M 69 + + SIGMOID B
37 M 68 + SIGMOID C
38 M 53 RECTUM C pT3 G2N1
39 M 80 + DESCENDING B pT3 G2 NO
40 F 62 SECTION 3 3 + CAECUM C PT3aNl G3
For Cytochrome data
+ Successful PCR amplification
Unsuccessful PCR amplification
For Ki-ras and p53 data
+ Mutation detected
Mutation not detected
No PCR No PCR amplification possible for DNA from whole gut lavage fluid.
For APC
Section x Section ofMCR in which APC mutation was identified
For RER (Analysis of tumour DNA)
MIN Number of unstable loci
+ TGFfi RI1mutation detected in tumour DNA
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